ãµãŒãžã«ã«ãã¹ã¯ãåžè£œãã¹ã¯ãçŸåšäœ¿çšãããŠããããã«ïŒä»ã®åœ¢æ ã®PPEä¿è·å ·ã䜿çšããã«ïŒäœ¿çšããŠããã³ãã19ãŠã€ã«ã¹ã®ææãæå¶ãã广ã¯ãªããšçµè«ã¥ããã®ã¯ç¡çããã¬ããšã§ããçŸåšã®èšŒæ ã¯ãé¡é¢ãã¹ã¯ãå®éã«æå®³ã§ããå¯èœæ§ã瀺åããŠãããäžé£ã®ãšããã³ã¹ã¯ããã¹ã¯ã¯ã»ãšãã©å¹æããªãããšã瀺ããŠãããÂ
ç§ã泚ç®ããŠããã®ã¯ãCOVIDã®ãã§ã€ã¹ãã¹ã¯ãšã20ã¶æè¿ããç¶ããŠããç§åŠçãªè£ä»ãã§ããããããç§ã¯ãã®ãã¹ã¯ã®è©±é¡ããããã¯ããŠã³å¶éæ¿çå šè¬ã«ã€ããŠã5äžãã£ãŒãã®ã¬ãã«ã§åãäžããããšæããŸããç§ã¯ãGuptaãKulldorffãBhattacharyaã®3人ãè¡ã£ãçŽ æŽãããç ç©¶ã®äžã«ç«ã£ãŠããã®åé¡ãèããŠããŸãã ã°ã¬ãŒãããªã³ãã³å®£èšïŒGBD)ããããŠç§ãšåãã幎霢ãªã¹ã¯å±€å¥ã¢ãããŒãã«åºã¥ãéäžåä¿è·ã匷ãæå±ããŠããã¹ã³ããã»ã¢ãã©ã¹å士(ãã©ã³ã倧統é ã®é¡§å)ã«ããåæ§ã®æšé²åã§ããÂ
ãšããã®ããç§ãã¡ã¯éåžžã«æ©ã段éã§ãããã¯ããŠã³ã¯å ¬è¡è¡çå²äžæå€§ã®èª€ãã§ããããšãèŠæããŠããããã§ããç§ãã¡ã¯ãã®æŽå²ãç¥ã£ãŠããããããããŸããããªãããšãç¥ã£ãŠããŸããããŸããCOVIDã®ãªã¹ã¯å±€å¥åã«ã€ããŠããéåžžã«æ©ãããç¥ã£ãŠããŸãããæ²ããããšã«ãç§ãã¡ã®åã©ããã¡ã¯Â 壿» ç åŸå  ãšÂ æè²äžã ãã§ãªãã®ãã§ãã æ±ã«äº€ããã°èµ€ããªãÂ äŒæ ¡ã®æ¹é æ°å幎 æ¥ããã€ããªãã£ãŒã®åäŸãã¡ãäžå¿ã«Â ãã®ãããªäœè£ã®ãªã人ãã¡ïŒãä»ã§ãå€ãã®äººããã¹ã¯ã®ççšãè¿«ãããççšããªããšçœ°ããããŸãã
以äžã«ãæ¯èŒå¹æç ç©¶ãé¢é£ãšããã³ã¹ããã€ã¬ãã«å ±åãããªããã¹ãã³ã°ã®ããšããã³ã¹æ¬äœãïŒn=167ã®ç ç©¶ããã³ãšããã³ã¹çïŒã玹ä»ãããçŸåšãŸã§ã®ãšããããã¹ã¯ã¯ãŠã€ã«ã¹ãæå¶ãã广ããªããç¹ã«åã©ãã«ã¯æå®³ã§ããããšãå®å®ãããšããã³ã¹ãšããŠæç¢ºã«ãªã£ãŠããŸããÂ
衚1ïŒCOVID-19ã®ãã§ã€ã¹ãã¹ã¯ãšãã¹ã¯ã®çŸ©ååãšå®³ã«é¢ãããšããã³ã¹
ãã¹ã¯å¹æÂ | |
1) ãã³ããŒã¯äººãã¹ã¯ççšè ã®SARS-CoV-2ææäºé²ã®ããã«ãä»ã®å ¬è¡è¡ç察çã«ãã¹ã¯ã®æšå¥šãå ããããšã®æå¹æ§, ãã³ãã¬ãŒã, 2021 | ãSARS-CoV-2ãžã®ææã¯ããã¹ã¯æšå¥šè 42åïŒ1.8%ïŒãå¯Ÿç §è 53åïŒ2.1%ïŒã§çºçããã矀éå·®ã¯-0.3ïŒ ãã€ã³ãïŒ95% CI, -1.2ïœ0.4ïŒ ãã€ã³ãïŒP = 0.38ïŒã§ãã£ãïŒãªããºæ¯ã0.82 [CI, 0.54ïœ1.23]; P = 0.33 ïŒãä»ã®å ¬è¡è¡ç察çãè£å®ããããã®ãµãŒãžã«ã«ãã¹ã¯ã®ççšæšå¥šã¯ãé©åºŠãªææçãããçšåºŠã®ç€ŸäŒçè·é¢ãããã³äžè¬çãªãã¹ã¯ã®äœ¿çšãäžè¬çã§ãªãå°å瀟äŒã«ãããŠãççšè ã®SARS-CoV-2ææçã50%ä»¥äžæžå°ãããªãã£ã". |
2) æ€ç«äžã®æµ·å µéå¡ã«ãããSARS-CoV-2ææã ã¬ãã£ãã£ã¢ã2020幎 | "æã ã®ç ç©¶ã¯ãäž»ã«è¥ãç·æ§ã®è»æ°å µã®ã°ã«ãŒãã«ãããŠã2é±éã®å³ããæ€ç«ã®éã«ãçŽ2%ãqPCRã¢ãã»ã€ã«ãã£ãŠSARS-CoV-2ã«éœæ§ãšãªã£ãããšã瀺ããŠãããè€æ°ã®ç¬ç«ãããŠã€ã«ã¹æ ªææã¯ã©ã¹ã¿ãŒã確èªããããã¹ãŠã®æ°å µã¯å±å å€ã«ãããŠåžžã«äºéã®åžè£œãã¹ã¯ãççšããŠããã" |
3) åŒåžåšç³»ãŠã€ã«ã¹ã®æ¡æ£ã黿¢ãŸãã¯äœæžããããã®ç©ççä»å ¥æ³2020幎ããžã§ãã¡ãŒãœã³ | ã9ã€ã®è©ŠéšïŒ3507人ïŒããããã¹ã¯ççšã¯éççšãšæ¯èŒããŠã€ã³ãã«ãšã³ã¶æ§çŸæ£ïŒILIïŒã®è»¢åž°ã«ã»ãšãã©å·®ããªãå¯èœæ§ããããšãã確信床ã®äœã蚌æ ãåŸãããŠããïŒãªã¹ã¯æ¯ïŒRRïŒ0.99ã95%ä¿¡é ŒåºéïŒCIïŒ 0.82ïœ1.18ïŒããã¹ã¯ççšã¯ããã¹ã¯ãççšããªãå Žåãšæ¯èŒããŠãå®éšå®€ã§ç¢ºèªãããã€ã³ãã«ãšã³ã¶ã®è»¢åž°ã«ããããã»ãšãã©å·®ããªããšããäžçšåºŠã®ç¢ºå®æ§ã®èšŒæ ãããïŒRR 0.91, 95% CI 0.66 to 1.26; 6詊éšïŒ3005人ïŒã"ç¡äœçºå詊éšã®ããŒã«çµæã¯ãå£ç¯æ§ã€ã³ãã«ãšã³ã¶æã®å»çã»å€ç§çšãã¹ã¯ã®äœ¿çšã«ããåŒåžåšãŠã€ã«ã¹ææã®æç¢ºãªæžå°ã瀺ããŠããªã...èåçãäœãã |
4) COVID-19ã«ãããã³ãã¥ããã£ã»ãã¹ãã³ã°ã®åœ±é¿ããã³ã°ã©ãã·ã¥ã«ãããã¯ã©ã¹ã¿ãŒç¡äœçºå詊éš2021幎ãã¢ãã©ã㯠Heneghan et al. | 2020幎11æãã2021幎4æãŸã§ããã³ã°ã©ãã·ã¥èŸ²æéšã«ãããã³ãã¥ããã£ã¬ãã«ã®ãã¹ã¯æ®åã®ã¯ã©ã¹ã¿ãŒç¡äœçºå詊éšïŒN=600æãæäººN=342,126人ãHeneghanã¯æ¬¡ã®ããã«æžããŠããŸãã ãã³ã°ã©ãã·ã¥èª¿æ»ãµãŒãžã«ã«ãã¹ã¯ã®å ŽåãCOVIDã®çåæ§ææã¯0ã22ïŒ æžå°ããåžè£œãã¹ã¯ã®å¹æã¯11ã21ïŒ æžå°ããŸããããããã£ãŠããããã®ç¡äœçºå詊éšã«åºã¥ããšã倧人çšãã¹ã¯ã®å¹æã¯ãªããããŸãã¯éå®çã§ãããšæãããŸãã |
5) SARS-CoV-2ã®æææ¡å€§ãæå¶ããããã®å°ååžãã¹ã¯ã®æå¹æ§ïŒæ¹å€çã¬ãã¥ãŒãªã¥ãŒ/CATOã2021幎 | ããã§ã€ã¹ãã¹ã¯ã®æå¹æ§ã«é¢ããå©çšå¯èœãªèšåºç蚌æ ã¯è³ªãäœããå©çšå¯èœãªæè¯ã®èšåºç蚌æ ã¯ããã§ã€ã¹ãã¹ã¯ãšãã¹ã¯ãªãã®å¯Ÿç §çŸ€ãæ¯èŒãã16ã®ç¹å®ã©ã³ãã 忝èŒè©Šéšã®ãã¡14ãæå³ããæ²»çéå£ã«ãããŠçµ±èšçã«ææãªå©çãèŠåºãããã»ãšãã©ãå¹åã瀺ããªãã£ããã®ã§ãã16ä»¶ã®å®éçã¡ã¿ã¢ããªã·ã¹ã®ãã¡ã8ä»¶ã¯ããã¹ã¯ã®å ¬çæšå¥šãæ¯æãããšããã³ã¹ãã©ããã«é¢ããŠäžæç¢ºãŸãã¯æ¹å€çã§ãããæ®ãã®8ä»¶ã¯ãäž»ã«äºé²ååã«åºã¥ããéããããšããã³ã¹ã§å ¬çãã¹ã¯ä»å ¥ãæ¯æããŠããã" |
6) éå»çæ©é¢ã«ãããæ°åã€ã³ãã«ãšã³ã¶å¯Ÿç-å人ä¿è·ãšç°å¢å¯Ÿç-ã«ã€ããŠCDC/Xiao, 2020 | "ãããã®å¯Ÿçã«é¢ãã14ã®ç¡äœçºåæ¯èŒè©Šéšããã®èšŒæ ã¯ãå®éšå®€ç¢ºå®ã€ã³ãã«ãšã³ã¶ã®äŒæã«å¯Ÿããå®è³ªçãªå¹æãæ¯æãããã®ã§ã¯ãªãã£ãã"ãããã®å®¶åºçšè©Šéšã§ãããã§ã€ã¹ãã¹ã¯çŸ€ã«ãããå®éšå®€ç¢ºå®ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹äºæ¬¡ææã®èããæžå°ãå ±åããŠããªãã"ãã§ã€ã¹ãã¹ã¯çŸ€ã«ãããILIãŸãã¯å®éšå®€ç¢ºå®ã€ã³ãã«ãšã³ã¶çäŸã®å šäœã®æžå°ã¯ãããã®è©Šéšã§ãææã§ãªãã£ãã |
7) ã·ãã©ããCOVID-19ã®ãã¹ã¯ã»ãã©ãŒã»ãªãŒã«ã¯ãµãŠã³ãããŒã¿ã«åºã¥ããªãããããœãŒã2020幎 | ãåžè£œãã¹ã¯ããã§ã€ã¹ã«ããŒã®æå¹æ§ãè£ä»ããããŒã¿ãéåžžã«éãããŠããããšã«åæããŸããããããåžè£œã®ãã¹ã¯ããã§ã€ã¹ã«ããŒã¯ãç¹ã«å³ããããã¿ãããŠããªãç¡çç¶ã®äººããã®ææã«å€§ããé¢äžããŠãããšèããããå°ããªåžå ¥æ§ç²åã«å¯Ÿãããã£ã«ã¿ãŒåéå¹çãéåžžã«äœãããšã瀺ãå®éšå®€ç ç©¶ã®ããŒã¿ããã...ããç§ãã¡ã¯äžè¬åžæ°ã®ãã¹ã¯ççšãæ¯æããŠããŸãããåžè£œã®ãã¹ã¯ããã§ã€ã¹ã«ããŒã¯ãå°ç²åã®æŸåºãé²ãèœåãã»ãšãã©ãªããå°ç²åã®åžå ¥ã«é¢ããŠéãããå人ä¿è·ããæäŸããªããããCOVID-19ææãæžãã广ã¯éå®çã§ãããšåŒãç¶ãçµè«ã¥ããŠããŸãã" |
8) Covid-19æä»£ã®ç é¢ã«ããããŠãããŒãµã«ãã¹ãã³ã°, Klompas/NEJM, 2020幎 | ãå»çæœèšå€ã§ã®ãã¹ã¯ççšã¯ãææäºé²ã«ã»ãšãã©å¹æããªãããšãåãã£ãŠããŸããå ¬è¡è¡çåœå±ã¯ãCovid-19ãžã®éå€§ãªæé²ããå°ãªããšãæ°åéïŒ10å以äžãããã¯30å以äžãšèšã人ãããïŒãçç¶ã®ããCovid-19æ£è ãš6ãã£ãŒã以å ã§å¯Ÿé¢ããŠæ¥è§Šããããšãšå®çŸ©ããŠããããããã£ãŠãå ¬å ±ã®å Žã§ã®å¶ç¶ã®æ¥è§Šã§Covid-19ã«ææããå¯èœæ§ã¯ã»ãšãã©ãªããå€ãã®å Žåããã¹ã¯ã®æ®åãæãã®ã¯ããã³ãããã¯ã«å¯Ÿããäžå®ã«å¯Ÿããåå°çåå¿ã§ãã...ããããå»ççŸå Žã§ã¯èšç®ãç°ãªããããããªããäœããããŸãããã¹ã¯ã¯ãã¬ãŠã³ãæè¢ãç®ã®ä¿è·å ·ãšãšãã«ãåŒåžåšç³»ãŠã€ã«ã¹ææçã®æçç¶æ£è ãã±ã¢ããéã«èšåºå»ãå¿ èŠãšããå人ä¿è·å ·ïŒPPEïŒã®äžæ žããªããã®ã§ããææã®è¡çãç®ã®ä¿è·ãæè¢ãã¬ãŠã³ãççšããªããã°ããã¹ã¯ã¯Covid-19ã®æŽ»åäžã®æ£è ãã±ã¢ããå»çåŸäºè ãä¿è·ããããšã¯ã§ããŸããããã¹ã¯ã ãã§ã¯ãåæã®Covid-19ã«ææããå»çåŸäºè ãæãæ±æããæ£è ãååã«ãŠã€ã«ã¹ãæ¡æ£ããããšãé²ãããšã¯ã§ããªããæ®éçãªãã¹ã¯ã ãã«çŠç¹ãåœãŠãããšã¯ãé説çã«ãããåºæ¬çãªææå¶åŸ¡çã®å®æœããæ³šæããããã°ãCovid-19ã®ææãããå¢ããããšã«ãªããããããªãã" |
9) å»çåŸäºè ããã³äžè¬åžæ°ã«ããããŠã€ã«ã¹æ§åŒåžåšææçäºé²ã®ããã®ãã¹ã¯ãPEER ã¢ã³ãã¬ã©ã·ã¹ãã ã¬ãã¥ãŒ, ãã¥ã°ã¬, 2020 | ããã®ã·ã¹ãããã£ãã¯ã¬ãã¥ãŒã§ã¯ããã¹ã¯ã®äœ¿çšããŠã€ã«ã¹æ§åŒåžåšææçã®ãªã¹ã¯ãäœæžããå¯èœæ§ããããšããéå®çãªãšããã³ã¹ãèŠåºãããŸãããå°å瀟äŒã§ã¯ããã¹ã¯äœ¿çšè ã«ãããŠãã€ã³ãã«ãšã³ã¶æ§çŸæ£ã®ãªã¹ã¯äœæžã®å¯èœæ§ãèŠåºããããå»çåŸäºè ã§ã¯ãã€ã³ãã«ãšã³ã¶æ§çŸæ£ããã®ä»ã®èšåºçåŒåžåšææçã®äºé²ã«N95ãã¹ã¯ãæå¹ã§ããå¯èœæ§ã瀺ãããããã€ã³ãã«ãšã³ã¶ããã®ä»ã®ç¢ºå®ãããŠã€ã«ã¹æ§åŒåžåšææçã®ãªã¹ã¯ã«ã€ããŠN95ãã¹ã¯ãšãµãŒãžã«ã«ãã¹ã¯ã®éã«å·®ããªãããšã瀺ãçµæã§ãã£ãããµãŒãžã«ã«ãã¹ã¯ã¯åžè£œãã¹ã¯ããåªããŠããå¯èœæ§ãããããããŒã¿ã¯1ã€ã®è©Šéšã«éãããŠããã" |
10) ãã³ãããã¯ã€ã³ãã«ãšã³ã¶ã®äŒææå¶ã«ãããå人é²è·æªçœ®ã®æå¹æ§ãã·ã¹ãããã£ãã¯ã¬ãã¥ãŒãšã¡ã¿ã¢ããªã·ã¹, ãœãŒã³ããŒã¹ã»ãã€ã¹ãã£ã³ã°ã¹, 2017 | ããã§ã€ã¹ãã¹ã¯ã®äœ¿çšã¯ææã§ãªãä¿è·å¹æããããããïŒOR = 0.53; 95% CI 0.16-1.71; I2 = 48%ïŒã®2009幎ãã³ãããã¯ã€ã³ãã«ãšã³ã¶ææã«å¯Ÿãã广ã確èªããŸããã" |
11) COVID-19ãçšãã宀å ãšã¢ããŸã«ã®æ¡æ£ã»èç©ã«é¢ããå®éšçæ€èšããã¹ã¯ãšææ°ã®å¹æã·ã£ãŒã2021幎 | "ããã§ããKN95ãªã©ã®é«å¹çãã¹ã¯ã¯ãããäžè¬çã«äœ¿çšãããŠããåžè£œãã¹ã¯ïŒ10%ïŒããµãŒãžã«ã«ãã¹ã¯ïŒ12%ïŒãããèŠããäžã®ãéå¹çãå€§å¹ ã«é«ãïŒR95ãšKN95ãã¹ã¯ã¯ãããã60%ãš46%ïŒããããã£ãŠå±å ã§ã®ç©ºæ°ææçã®äŒæãç·©åããäžã§äŸç¶ãšããŠæšå¥šã§ããéžæãšãªã£ãŠããŸãã" |
12) ãã§ã€ã¹ãã¹ã¯ãã€ããŠã®éåïŒæªéã®å£ãæ±ã£ãŠããã®ãïŒ, ãã£ã³ãã©ã»ã«ã©ã³, 2020 | ããã§ã€ã¹ãã¹ã¯ãççšããŠã®éåã¯ãå©çšå¯èœãªé žçŽ ãæžå°ãããå®è³ªçãªäºé žåççŽ ã®äº€æã劚ãã空æ°ãã©ããã³ã°ãå¢å ãããå¯èœæ§ããããŸããéåŒåžäœé žçŽ ã¯ãé žæ§ç°å¢ãå¿èã®éè² è·ã嫿°æ§ä»£è¬ãè èã®éè² è·ãå¢å ãããæ ¢æ§çŸæ£ã®æ ¹æ¬çãªç æ ãæªåãããå¯èœæ§ããããŸããããã«ã以åã®èããšã¯ç°ãªããéåäžã®ãã§ã€ã¹ãã¹ã¯ããŠã€ã«ã¹ã®é£æ²«ææããããã«ä¿è·ããããšã䞻匵ãã蚌æ ã¯ååšããªãã" |
13) çŸä»£ã®æè¡å®€ã«ãããæè¡çšãã§ã€ã¹ãã¹ã¯-ã³ã¹ãé«ã§äžå¿ èŠãªååŒãïŒÂ ãããã§ã« 1991幎 | ãæ°ããæè¡å®€ã®è©Šé転åŸã空æ°ã®åãã調æ»ãããšãããæè¡å°ããéšå±ã®åšèŸºã«åãã空æ°ã®æµããããããšãããããŸãããæè¡å°ãã1ã¡ãŒãã«é¢ããå Žæã«ç«ã€ããã¹ã¯ãããŠããªãç·å¥³ã®ãã©ã³ãã£ã¢ã«ãã£ãŠé£æ£ããå£è å 埮çç©å¢ã¯ãæè¡å°äžã«çœ®ãããé²åºããæ²æ®¿ãã¬ãŒããæ±æããããšãã§ããŸããã§ãããåŒ·å¶ææ°ã®ããæè¡å®€ã§åãéã¹ã¯ã©ãã¹ã¿ããã«ãããã§ã€ã¹ãã¹ã¯ã®ççšã¯äžèŠãšæãããã" |
14) ãããžå·¡ç€Œè ã®ãŠã€ã«ã¹æ§åŒåžåšææçã«å¯Ÿãããã§ã€ã¹ãã¹ã¯ïŒå°é£ãªã¯ã©ã¹ã¿ãŒç¡äœçºå詊éš2020幎ãã¢ã«ãã§ã©ãŒãª | "intention-to-treatè§£æã«ããããã§ã€ã¹ãã¹ã¯ã®äœ¿çšã¯ãå®éšå®€ã§ç¢ºèªããããŠã€ã«ã¹æ§åŒåžåšææçïŒãªããºæ¯ïŒ»ORã1.4ïŒ95%ä¿¡é ŒåºéCIã0.9ïœ2.1ãpïŒ0.18ïŒã«ãèšåºåŒåžåšææçã«ãæå¹ã§ã¯ãªãããã§ãã(OR, 1.1; 95% CI, 0.9 ïœ 1.4, pïŒ0.40)"ã |
15) 簡æåŒåžä¿è·å ·-20ã1000nmãµã€ãºã®ç²åã«å¯Ÿããåžè£œãã¹ã¯ãšäžè¬çãªåžçŽ æã®æ¿Ÿéæ§èœã®è©äŸ¡, ã¬ã³ã¬ãµããŒ, 2010 | "ç ç©¶ã§åŸãããçµæã¯ãäžè¬çãªåžçŽ æã¯ãåŒæ°ã«å«ãŸãããŠã€ã«ã¹å«æç²åã®ãµã€ãºç¯å²ã®ãã®ãå«ãããç²åã«å¯ŸããŠéççãªä¿è·ãæäŸããå¯èœæ§ãããããšã瀺ããŠããŸãã" |
16) N95ã¬ã¹ãã¬ãŒã¿ãšãµãŒãžã«ã«ãã¹ã¯ã®åŒåžæ§èœïŒçްèããã³ãŠã€ã«ã¹ã®ç²ååŸç¯å²ã衚ãNaClãšã¢ããŸã«ãçšãã被éšè ã«ããè©äŸ¡ãªãŒã2008幎 | "ãã®ç ç©¶ã¯ãN95ãã£ã«ã¿ãŒä»ããã§ã€ã¹ããŒã¹ã¬ã¹ãã¬ãŒã¿ãŒãããã¯ããªã¢ãšãŠã£ã«ã¹ã«å¯ŸããŠæåŸ ãããä¿è·ã¬ãã«ãéæã§ããªãå¯èœæ§ã瀺ããŠããŸããN95ã¬ã¹ãã¬ãŒã¿ãŒã®åŒæ°åŒã¯åŒåžä¿è·ã«åœ±é¿ãäžãããåŒåžæµæãæžããããã®é©åãªä»£æ¿ææ®µãšæãããã" |
17) ãã«ã¹ã±ã¢ç£æ¥ã§äœ¿çšããããã¹ã¯ã®ãšã¢ããŸã«ééæ§ãšãªãŒã¯ç¹æ§ãŠã§ãŒããŒã1993 | "æœåšçã«å±éºãªãµããã¯ãã³ãµã€ãºã®ãšã¢ããŸã«ãå«ãç°å¢ã§ã¯ããµãŒãžã«ã«ãã¹ã¯ã«ããä¿è·ã¯äžååã§ããå¯èœæ§ããããšçµè«ä»ããŠããã" |
18) ã¯ãªãŒã³ãµãŒãžã§ãªãŒã«ãããæè¡åµææé²æ¢çšãã£ã¹ããŒã¶ãã«ãã§ã€ã¹ãã¹ã¯, ãŽã£ã³ã»ã³ã, 2016 | "3ã€ã®è©Šéšãå«ã¿ãåèš2106人ãåå ããããããã®è©Šéšã§ããã¹ã¯ççšçŸ€ãšéççšçŸ€ã®ææçã«çµ±èšçã«ææãªå·®ã¯ãããŸããã§ããã"éãããçµæãããæè¡ããŒã ã®ã¡ã³ããŒã«ããæè¡çšãã§ã€ã¹ãã¹ã¯ã®ççšããæž æœæè¡ãåããæ£è ã®æè¡åµææçã«äœããã®åœ±é¿ãäžãããã©ããã¯äžæã§ãã" |
19)Â äœ¿ãæšãŠæè¡çšãã§ã€ã¹ãã¹ã¯ïŒã·ã¹ãããã£ãã¯ã¬ãã¥ãŒãªããã2005 | "éãããçµæãããæè¡çšãã§ã€ã¹ãã¹ã¯ã®ççšããæž æœãªæè¡ãåããæ£è ããã«å®³ãå©çããããããã©ããã¯äžæã§ãã" |
20) 3çš®é¡ã®åŸ®çç©ãšã¢ããŸã«ã«å¯Ÿããå»ççšäžç¹åžã®ãéæ§èœã®æ¯èŒ, 島åŽÂ , 2018 | "ãã£ãŒX174ãã¡ãŒãžãšã¢ããŸã«ãçšãããã£ã«ã¿ãŒå¹ç詊éšã§ã¯ããã£ã«ã¿ãŒæ§é ãæããäžç¹åžã®ä¿è·æ§èœããã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ãªã©ã®å®éã®ç åäœã«å¯Ÿãããã®ãšæ¯èŒããŠé倧è©äŸ¡ããå¯èœæ§ããããšçµè«ä»ããŸããã" |
21) ã€ã³ãã«ãšã³ã¶ææäºé²ã®ããã®ãã¹ã¯ãšåŒåžåšã®äœ¿çšïŒç§åŠçæ ¹æ ã®ã·ã¹ãããã£ãã¯ã»ã¬ãã¥ãŒ21) ã€ã³ãã«ãšã³ã¶ææäºé²ã®ããã®ãã¹ã¯ãšåŒåžåšã®äœ¿çšïŒç§åŠç蚌æ ã®ç³»çµ±çã¬ãã¥ãŒ, ãã³-ã¬ã¶, 2012 | ã€ã³ãã«ãšã³ã¶ææäºé²ã®ããã®ãã¹ã¯ãšåŒåžåšã®äœ¿çšïŒç§åŠç蚌æ ã®ç³»çµ±çã¬ãã¥ãŒãã©ã®ç ç©¶ãããã¹ã¯/åŒåžåšã®äœ¿çšãšã€ã³ãã«ãšã³ã¶ææã«å¯Ÿããé²åŸ¡ã®éã«æ±ºå®çãªé¢ä¿ã確ç«ããŠããªãããã¹ã¯ã®äœ¿çšã¯ãå人ä¿è·ãç¹ã«ææè¡çã®äžç°ãšããŠè¡ãã®ãæåã§ããããšã瀺åãã蚌æ ãããã" |
22) ãã³ãããã¯æã®å»çåŸäºè ã®é¡é¢ä¿è·ïŒã¹ã³ãŒãã³ã°ã¬ãã¥ãŒ, ãŽãã€, 2020 | ãå€ç§çšãã¹ã¯ãšæ¯èŒããŠãN95åŒåžåšã¯å®éšå®€è©Šéšã§åªããæ§èœã瀺ããå ¥é¢æ£è ç°å¢ã§ã¯åªããä¿è·ãæäŸãã倿¥æ£è ç°å¢ã§ã¯åçã«æ©èœããå¯èœæ§ããããŸãããµãŒãžã«ã«ãã¹ã¯ãšN95åŒåžåšã®ä¿è·å¯Ÿçã«ã¯ãäœ¿çšæéã®å»¶é·ãå䜿çšãæ±æé€å»ããããããããã®å¯Ÿçã¯ä¿è·æ§èœãå£ãå¯èœæ§ããããéããããšããã³ã¹ã§ã¯ããããå»çã°ã¬ãŒãã®ä¿è·å ·ãå ¥æã§ããªãå Žåã¯ãåå©çšãå³åžã®ãã¹ã¯ã䜿çšãã¹ãã§ãããšãããŠããã" |
23) ã·ã³ã¬ããŒã«ã«ãããäžè¬åžæ°ã®N95ãã¹ã¯ççšç¿ç床è©äŸ¡, Yeung, 2020 | ããããã®çµæã¯ãCOVID-19ã®æµè¡æéäžã«äžè¬åžæ°ãN95ãã¹ã¯ã䜿çšããªããããçŸåšæšå¥šãããŠããããšãè£ä»ãããã®ã§ãã5 äžè¬åžæ°ã«ããN95ãã¹ã¯ã®äœ¿çšã¯ã广çãªé²è·ã«ã€ãªãããªãã©ãããã誀ã£ãå®å¿æãäžãããããããªããN95ãã¹ã¯ã«ãšã©ãŸãããäžè¬åžæ°ã®ãµãŒãžã«ã«ãã¹ã¯ççšã«é¢ããç¿ç床ãè©äŸ¡ããå¿ èŠããããã |
24) åžè£œãã§ã€ã¹ãã¹ã¯ã®ç²åç¶ç©è³ªæé²äœæžå¹æã®è©äŸ¡, é迊, 2017 | "æšæºçãªN95ãã¹ã¯ã®æ§èœãå¯Ÿç §ãšããŠåžè£œãã¹ã¯ãšæ¯èŒããçµæãåžè£œãã¹ã¯ã¯2.5ÎŒmæªæºã®ç²åããå人ãä¿è·ããäžã§ããããªå©çãããªãããšã瀺åãããã" |
25)Â æ¥æ¬ã«ãããå»çåŸäºè ã®é¢šéªã®çºçãæžå°ãããããã®å€ç§çšãã§ã€ã¹ãã¹ã¯ã®äœ¿çšïŒç¡äœçºåæ¯èŒè©Šéšãžã§ã€ã³ãã¹ã2009幎 | "å»çåŸäºè ã«ããããã§ã€ã¹ãã¹ã¯ã®äœ¿çšã¯ã颚éªã®çç¶ã颚éªãã²ããšããç¹ã§æçã§ããããšã¯èšŒæãããŠããŸããã" |
26) å»çåŸäºè ã®ã€ã³ãã«ãšã³ã¶äºé²ã®ããã®N95åŒåžåšãšå»ççšãã¹ã¯ã®æ¯èŒ, ã©ãããããã2019幎 | "倿¥å»çåŸäºè ã«ãããŠãæ¬è©Šéšåå è ãççšããN95ã¬ã¹ãã¬ãŒã¿ãšå»ççšãã¹ã¯ã¯ãæ€æ»ç¢ºå®ã€ã³ãã«ãšã³ã¶ã®çºççã«ææå·®ãèªããªãã£ãã" |
27) ãã¹ã¯ã®ççšã¯COVID-19ã®èå»¶ãæžå°ããããå¢å ããããïŒÂ ã¯ããã¢ããïŒ2020 | "å°éå®¶ã«ããç ç©¶ã®èª¿æ»ã«ãããšãïŒç¹å®ã®ç°å¢ã§ã®ãã¹ã¯ççšã§ã¯ãªãïŒæ®éçãªãã¹ã¯ççšã¯ããã¹ã¯ççšè ãããã¹ã¯ãããŠããªã人ãžã®åŒåžåšç³»ãŠã£ã«ã¹ã®ææãæžå°ãããªãããšã瀺ãããŠããã" |
28) ãã¹ãã³ã°ããšããã³ã¹ã®æ éãªã¬ãã¥ãŒ2021幎ãã¢ã¬ããµã³ã㌠| "å®éãå€ç§çšãã¹ã¯ãåžè£œãã¹ã¯ãçŸåšã®ããã«äœ¿çšããŠããã³ãã19ãŠã€ã«ã¹ã®ææãæå¶ãã广ã¯å šããªããçŸåšã®ãšããã³ã¹ã§ã¯ããã§ã€ã¹ãã¹ã¯ãå®éã«æå®³ã§ããå¯èœæ§ã瀺åããŠãããšçµè«ã¥ããããšã¯ãçŸæç¹ã§ã¯ç¡çãªããšã§ã¯ãããŸããã" |
29) 11ã®å€æ¥å»çæœèšã«ããã18æ³ä»¥äžã®æçç¶æäººã«ãããCOVID-19ã«é¢é£ããã³ãã¥ããã£ããã³å¯æ¥æ¥è§ŠæŽé²-ç±³åœã2020幎7æ, ãã£ãã·ã£ãŒ, 2020 | ç±³åœã®11ã®åŠè¡å»çæœèšã®å€æ¥æ£è ã§ãããSARS-CoV-2æ€æ»çµæãéœæ§ããã³é°æ§ã®æçç¶æäººïŒNïŒ314ïŒ*ã®ç¹åŸŽãå ±å-ç±³åœã2020幎7æ1æ¥ãã29æ¥ãŸã§ãææè ã®80%ãã»ãŒå šå¡ãŸãã¯ãã§ã€ã¹ãã¹ã¯ãççšããããšãæããã«ãªããŸããã 倧æµã®å Žå. |
30) 欧å·ã«ãããCOVID-19ã«å¯Ÿããéè¬ç©ä»å ¥ã®åœ±é¿ïŒæºå®éšçç ç©¶ãã³ã¿ãŒã2020幎 | å ¬å ±ã®å Žã§ã®ãã§ã€ã¹ãã¹ã¯ã¯ãçºççã®äœäžãšé¢é£ããªãã£ãã |
31) ãšããã³ã¹ã®æ¬ åŠãæ¿æ²»ã§èŠãé ã, CEBM, Heneghan, 2020幎 | 20幎ã«ããããã³ãããã¯å¯Ÿçã«ããããããããã¹ã¯ççšã®äŸ¡å€ã«ã€ããŠã¯ããªãã®äžç¢ºå®æ§ãããããã ããäŸãã°ãåžè£œãã¹ã¯ã®ææçãé«ãã®ã¯ãåžè£œãã¹ã¯ã®å®³ã«ãããã®ãããããŸããããå»ççšãã¹ã¯ã®å©ç¹ã«ãããã®ãããããŸããã æè¿çºè¡šãããæ°å€ãã®ã·ã¹ãããã£ãã¯ã¬ãã¥ãŒã¯ããã¹ãŠåããšããã³ã¹ããŒã¹ãå«ãã§ããã®ã§ãåœç¶ã®ããšãªãããããããåãçµè«ã«éããŠããã" |
32) ã¹ãã€ã³ã»ã«ã¿ã«ãŒãã£å°æ¹ã®282ã®ã¯ã©ã¹ã¿ãŒã«ãããCOVID-19ã®äŒæïŒã³ããŒãç ç©¶ããŒã¯ã¹ã2021幎 | "æ¥è§Šè ã«ãããã¹ã¯äœ¿çšå ±åãææšæ£è ã®å¹Žéœ¢ãæ§å¥ãååèª¿æ»æã®ææšæ£è ã®åŒåžåšçç¶ã®æç¡ãšãææãªã¹ã¯ã®é¢é£ã¯èªããããŸããã§ããã" |
33) æµè¡æ§ã€ã³ãã«ãšã³ã¶ã®ãªã¹ã¯ãšåœ±é¿ã軜æžããããã®éè¬ç©çãªå ¬è¡è¡çææ®µ, WHO, 2020 | "10ä»¶ã®RCTãã¡ã¿åæã«å«ãŸãããã§ã€ã¹ãã¹ã¯ãæ€æ»ç¢ºå®ã€ã³ãã«ãšã³ã¶ã®æææå¶ã«æå¹ã§ããããšã瀺ã蚌æ ã¯ãªãã£ãã" |
34) ã¢ã¡ãªã«ã®å¥åŠãªéç§åŠçãã¹ã¯ãŠãã¹ã³ã2020幎 | "ããå ±åæžã§ã¯ã" "ã®èгå¯ã«åºã¥ããŠçµè«ãåºããŠãããã¹ãã³ããã."  å¥ã®Â ã¯ãæ¥æ§åŒåžåšçŸæ£ã®çç¶ã2ã€ä»¥äžãã人ãžã®ãµãŒãžã«ã«ãã¹ã¯ã®äœ¿çšãåæããŸãããã¡ãªã¿ã«Â ã²ãšã€ãç ç©¶ããŠããªã ãŸããåžè£œãã¹ã¯ãäžè¬äººã®å®éã®ãã¹ã¯äœ¿çšç¶æ³ïŒãŸãã¯èª€çšïŒã説æããçç¶ã®ãªã人ãåºããã¹ã¯ãççšããããšã®æå¹æ§ã蚌æãããã®ã¯ãããŸããã§ããã å¥åº·ãªäººãçæŽ»ããäžã§ãç¹ã«å±å€ã§ã¯ãã¹ã¯ãççšããæ¹ãè¯ããšãã蚌æ ã¯å šããªãã£ãã®ã§ãã |
35) COVID-19ãªã©ã®åŒåžåšçŸæ£ãäºé²ããããã®ãã§ã€ã¹ãã¹ã¯ãšåæ§ã®ããªã¢ãè¿ éãªã·ã¹ãããã£ãã¯ã¬ãã¥ãŒ2020幎ããã¬ã€ããŒã | "31ä»¶ã®é©æ Œç ç©¶ïŒ12ä»¶ã®RCTãå«ãïŒã28ä»¶ã®ç ç©¶ã«ãããŠãäžæ¬¡äºé²ãšäºæ¬¡äºé²ã®æ»æçã®ãã©ãã£ãã·ã³ã»ã·ã¹ãšã©ã³ãã 广ã¡ã¿ã¢ããªã·ã¹ãè¡ããããRCTã«åºã¥ããšããã§ã€ã¹ãã¹ã¯ã®ççšã¯ãå°å瀟äŒã®ã«ãžã¥ã¢ã«ãªæ¥è§Šã«ããäžæ¬¡ææã«å¯ŸããŠãããããã«äºé²å¹æããããææè ãšéææè ã®äž¡æ¹ããã§ã€ã¹ãã¹ã¯ãççšããå Žåãå®¶åºå ææã«å¯ŸããŠäžçšåºŠã®äºé²å¹æããããšçµè«ã¥ãããããããããRCTã¯ãã§ã€ã¹ãã¹ã¯ã䜿çšããã³ã³ãã©ã€ã¢ã³ã¹ãšã³ã³ãããŒã«ãäžååã§ããããšãå€ãã |
36) å€è£ ã®å¹Žã¯ãŒãã¹ã2020幎 | ãç§ãã¡ã®ç€ŸäŒã®å¥åº·ãªäººã ã¯ãå¥åº·ã§ããããšãçç±ã«çœ°ããããã¹ãã§ã¯ãããŸãããããã¯ãŸãã«ãããã¯ããŠã³ãè·é¢ããã¹ã¯ã®çŸ©åä»ããªã©ãããã§ããããã«ã»ã»ã»åã©ããã¡ã¯é¡ãèŠãã¹ãã§ã¯ãªãã®ã§ããç§ãã¡ã¯çãåžžã«èªåã®çœ®ãããç°å¢ãšçžäºäœçšããå¿ èŠããããããã¯ç¹ã«åã©ããã¡ã«åœãŠã¯ãŸããŸããããããããšã§ãå ç«ã·ã¹ãã ãçºéããã®ã§ãã圌ãã¯æããªã¹ã¯ã®äœãã°ã«ãŒããªã®ã§ãããã¹ã¯ççšçŸ©ååãã¯å®ã«ã°ããããèãæã€ãããªåå¿ã§ãããããã¯ããŠã³ãåŠæ ¡ééãšãšãã«ãæ²æšãªæ¿çã®ãŽãç®±ã«æšãŠãããã¹ããã®ã§ããããã®äººã®ææ¡ããã¹ãŠç²ç®çã«æ¯æããããšãªãããã®äººã«æç¥šããã°ããã®ã§ãïŒ" |
37) ã¹ãŠã§ãŒãã³ã«ããããªãŒãã³ã¹ã¯ãŒã«ãCovid-19ãåäŸãšæåž«ã®çœ¹æ£ç, ã«ããŽã£ã°ãœã³, 2020 | "ã¹ãŠã§ãŒãã³ã§1æ³ãã16æ³ã®åã©ã195äž1905人ïŒ2019幎12æ31æ¥æç¹ïŒãå¯Ÿè±¡ã«æ€æ»ã宿œ...ã¹ãŠã§ãŒãã³ã§ã¯ç€ŸäŒçè·é¢ã眮ãããšãæšå¥šãããŠãããããã§ã€ã¹ãã¹ã¯ã®ççšã¯æšå¥šãããŠããªãã£ã...Covid-19ã®åã©ãã¯æ»äº¡ããªãã£ã"... |
38) äºéãã¹ã¯ã®å¹æã¯éå®çãæ¥æ¬ã®ã¹ãã³ã³ãçºèŠ, Reidy, 2021 | "ã¹ãŒããŒã³ã³ãã¥ãŒã¿ã§é£æ²«ã®é£æ£ãã¢ãã«åããæ¥æ¬ã®ç ç©¶ã«ãããšã2æã®ãã¹ã¯ãççšããŠãããããã£ããããäœ¿ãæšãŠãã¹ã¯1æãšæ¯èŒããŠãã³ãããŠã€ã«ã¹ãéã¶å¯èœæ§ã®ãã飿²«ã®æ¡æ£ãé²ã广ã¯éå®çã§ãã "ãšã®ããšã§ãã |
39) åŒåžåšç³»ãŠã€ã«ã¹ã®æ¡æ£ã黿¢ãŸãã¯äœæžããããã®ç©ççä»å ¥ã第1éš - ãã§ã€ã¹ãã¹ã¯ãç®ã®ä¿è·ã人ãšã®è·é¢ã®åãæ¹ïŒç³»çµ±çã¬ãã¥ãŒãšã¡ã¿ã¢ããªã·ã¹2020幎ããžã§ãã¡ãŒãœã³ | "ä»ã®ææ®µãçšããªãé¡é¢ããªã¢ã®äœ¿çšã«ã€ããŠæšå¥šãè¡ãã«ã¯ãååãªèšŒæ ããªãã£ãããµãŒãžã«ã«ãã¹ã¯ãšN95ã¬ã¹ãã¬ãŒã¿ã®éãã瀺ã蚌æ ã¯äžååã§ãããæ€ç«ã®æå¹æ§ãæ¯æãã蚌æ ã¯éãããŠããã" |
40) COVID-19ã®æææ¡å€§ãæããããã«ãåŒåžåšçç¶ãæããªãå°åäœæ°ã¯ãã§ã€ã¹ãã¹ã¯ãççšãã¹ãã§ããããïŒÂ NIPH, 2020 | "éå»ççšãã§ã€ã¹ãã¹ã¯ "ã«ã¯ãæ§ã ãªè£œåããããŸããå°å瀟äŒã«ãããéå»ççšãã§ã€ã¹ãã¹ã¯ã®æå¹æ§ã«ã€ããŠã¯ãä¿¡é Œã§ãã蚌æ ã¯ãªãã補åã«ãã£ãŠå¹æã«ããªãã®ã°ãã€ãããããšæããããããããç°ãªã補åãå°å瀟äŒã§äœ¿çšãããå Žåã®æå¹æ§ã®æœåšçãªéãã«ã€ããŠã¯ãå®éšå®€ç ç©¶ããã®éããã蚌æ ãããªãã" |
41) æè¡å®€ã§ã®ãã¹ã¯ã¯å¿ èŠã§ããïŒÂ ãªã¢ãŒã1981 | ããã¹ã¯ãã€ããã«é»ã ãšäœæ¥ããããšã§ãæ±æãæå°éã«æããããšãã§ãããšæãããŸããã³ã³ã¿ãããŒã·ã§ã³ãçŽ°èæ°ãã¹ã¯ã¯ãŒã ã®æ¡æ£ãšã®é¢ä¿ãã©ãã§ããããã¹ã¯ççšã嵿æãæžãããšããçŽæ¥çãªèšŒæ ã¯ãªãã" |
42) ãµãŒãžã«ã«ãã¹ã¯ã¯ããªã¹ã¯äœæžã®ããã«ã¯äžåãã§ã, ããŒã«ãœã³, 2016 | "2010å¹Žã®æç¹ã§ãç±³åœç§åŠã¢ã«ãããŒã¯ãã³ãã¥ããã£ç°å¢ã«ãããŠã"ãã§ã€ã¹ãã¹ã¯ã¯ãççšè ãåŒåžåšç³»ã®å±éºãžã®æé²ããä¿è·ããããã«èšèšãèªå®ããããŠããªã "ãšå®£èšããŠããŸããå€ãã®ç ç©¶ããå®¶åºç°å¢ã«ããããµãŒãžã«ã«ãã¹ã¯ãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®ææãé²ãã®ã«æå¹ã§ãªãããšãæããã«ããŠããŸãã" |
43) ãããžæ»åšäžã®ãŠã€ã«ã¹æ§åŒåžåšææäºé²ã«ããããã§ã€ã¹ãã¹ã¯ãšãã§ã€ã¹ãã¹ã¯ãªãã®æ¯èŒïŒã¯ã©ã¹ã¿ãŒç¡äœçºåãªãŒãã³ã©ãã«è©Šéš, ã¢ã«ãã§ã©ãŒãª, 2019 | "ãã§ã€ã¹ãã¹ã¯ã®äœ¿çšã¯ããããžå·¡ç€Œè ã«ãããèšåºçãŸãã¯å®éšå®€ã§ç¢ºèªããããŠã€ã«ã¹æ§åŒåžåšææçãäºé²ããªã". |
44) COVID-19æä»£ã®ãã§ã€ã¹ãã¹ã¯ãå¥åº·ä»®èª¬, ãŽã¡ã€ã³ã»ã«ãã€ã , 2021 | ãCOVID-19ã®äºé²ä»å ¥ãšããŠãã§ã€ã¹ãã¹ã¯ãççšããããšã®å®å šæ§ãšæå¹æ§ã¯ãæ¢åã®ç§åŠç蚌æ ã§ã¯çåèŠãããŠããŸããSARS-CoV-2ãCOVID-19ã®ãããªãŠã€ã«ã¹æ§ææçã®ãããããããžã®ææãé²ãã«ã¯ãå»ççšã»éå»ççšãã§ã€ã¹ãã¹ã¯ã®ãããã广ããªãããšã瀺åãããŠããããã§ã€ã¹ãã¹ã¯ã®ççšã«å察ãããã®ã§ããããã§ã€ã¹ãã¹ã¯ã®ççšã¯ãçççã»å¿ççã«å€§ããªæªåœ±é¿ãåãŒãããšãå®èšŒãããŠããŸããäœé žçŽ ãé«çé žãæ¯åããé žæ§åºŠäžæãæ¯æ§ãææã»ã¹ãã¬ã¹åå¿ã®æŽ»æ§åãã¹ãã¬ã¹ãã«ã¢ã³ã®äžæãå ç«æå¶ãç²åŽãé çãèªç¥èœåã®äœäžããŠã€ã«ã¹æ§ã»æææ§çŸæ£ã®çŽ å ãæ ¢æ§ã¹ãã¬ã¹ãäžå®ãæãã€ãªã©ã§ãã" |
45) ã€ã³ãã«ãšã³ã¶ææäºé²ã®ããã®ãã¹ã¯ãšåŒåžåšã®äœ¿çšïŒç§åŠç蚌æ ã®ç³»çµ±çã¬ãã¥ãŒ, ãã³-ã¬ã¶, 2011 | ããã¹ã¯/åŒåžåšã®äœ¿çšãšã€ã³ãã«ãšã³ã¶ææäºé²ã®éã«æ±ºå®çãªé¢ä¿ãããããšãç«èšŒããç ç©¶ã¯ãªãããã¹ã¯ã®äœ¿çšã¯ãå人ä¿è·ãç¹ã«ææè¡çã®ããã±ãŒãžã®äžéšãšããŠè¡ãã®ãæåã§ããããšã瀺åãããšããã³ã¹ããããŸãã" |
46) ãã§ã€ã¹ãã¹ã¯ã¯å¹æçãïŒãã®æ ¹æ ., ã¹ã€ã¹ã»ããªã·ãŒã»ãªãµãŒã, 2021 | "ã»ãšãã©ã®ç ç©¶ã§ãäžè¬éå£ã«ããããã§ã€ã¹ãã¹ã¯ã®æå¹æ§ã«ã€ããŠã¯ãå人çšä¿è·å ·ãšããŠãçºçæºå¯ŸçãšããŠããã»ãšãã©èšŒæ ããªãããšã倿ããŸããã" |
47) è¡åŸåµå·ææãšãµãŒãžã«ã«ãã§ã€ã¹ãã¹ã¯ãå¯Ÿç §ç ç©¶, ãããã«, 1991 | ããããã®çµæã¯ããã¹ã¯ã®äœ¿çšã«ã€ããŠåèããå¿ èŠãããããšã瀺ããŠããŸãããã¹ã¯ã¯ãææããè¡æ¶²ã®æ»Žäžãç©ºæ°ææããæè¡ããŒã ãå®ãããã«äœ¿çšããããããããªãããå¥åº·ãªæè¡ããŒã ãæè¡ããæ£è ãå®ãããšã¯èšŒæãããŠããªãã" |
48) å·ã¬ãã«ã®COVID-19å°ã蟌ãã«ããããã¹ã¯ã®çŸ©ååãšäœ¿çšã®æå¹æ§ã²ã©ã2021幎 | "ãã¹ã¯ã®çŸ©ååãšäœ¿çšã¯ãCOVID-19ã®æé·æ¥å¢æã®å·ã¬ãã«ã®COVID-19æ®åã®é ããšã¯é¢é£ããªã"ã |
49) ãã¹ã¯ççšçŸ©ååãå®å šã§ãªãã广ããªããäžé埳ã§ãã20ã®çç±2021幎ããã³ãªãŒ | "A CDCãè³éæäŸããã¬ãã¥ãŒÂ ã2020幎5æã«ãã¹ãã³ã°ã«é¢ããçµè«ã«è³ã£ãã"ææè¡çããã§ã€ã¹ãã¹ã¯ã®æœåšçãªå¹æã¯ã¡ã«ããºã ç ç©¶ã§è£ä»ããããŠãããããããã®å¯Ÿçã«é¢ãã14ã®ã©ã³ãã 忝èŒè©Šéšããã®ãšããã³ã¹ã¯ãå®éšå®€ç¢ºå®ã€ã³ãã«ãšã³ã¶ã®äŒæã«å¯Ÿããå®è³ªçãªå¹æãè£ä»ããŠããªã...å®¶åºã§ã®ç ç©¶ã§ã¯ããã§ã€ã¹ãã¹ã¯çŸ€ã«ãããäºæ¬¡å®éšå®€ç¢ºå®ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ææã®ææãªæžå°ãå ±åãããã®ã¯ãªãã£ãã"ãã¹ã¯ãéåžžã®ã€ã³ãã«ãšã³ã¶ãæ¢ããããªããªããSAR-CoV-2ãã©ããã£ãŠæ¢ããããã®ã ããïŒ" |
50) å»çåŸäºè ã«ãããåžè£œãã¹ã¯ãšå»ççšãã¹ã¯ã®æ¯èŒã®ã¯ã©ã¹ã¿ãŒç¡äœçºå詊éš, ãããã³ã¿ã€ã¢, 2015 | "åžè£œãã¹ã¯ "åã®RCTãåžè£œãã¹ã¯ã®äœ¿çšã«æ³šæãä¿ãçµæã«ãããã¯ãåŽåå®å šè¡çãèããäžã§éèŠãªç¥èŠã§ãããæ¹¿æ°ã®æ»çãåžè£œãã¹ã¯ã®å䜿çšããéæ§èœã®äœäžã«ãããææãªã¹ã¯ãé«ãŸãå¯èœæ§ãããããã¹ãŠã®ææã¢ãŠãã«ã ã®å²åã¯åžè£œãã¹ã¯çŸ€ã§æãé«ããILIã®å²åã¯å»ççšãã¹ã¯çŸ€ãšæ¯èŒããŠåžè£œãã¹ã¯çŸ€ã§çµ±èšçã«ææã«é«ãã£ãïŒçžå¯Ÿãªã¹ã¯ïŒRRïŒ = 13.00, 95% CI 1.69ïœ100.07ïŒïŒãŸããåžè£œãã¹ã¯ã¯å¯Ÿç §çŸ€ã«æ¯ã¹ãILIçºççãææã«é«ãã£ãããã¹ã¯ã®äœ¿çšç¶æ³å¥ã®è§£æã§ã¯ãILIïŒRR=6.64ã95% CI 1.45ïœ28.65ïŒ ãšå®éšå®€ç¢ºå®ãŠã€ã«ã¹ïŒRR=1.72ã95% CI 1.01ïœ2.94ïŒ ã¯åžè£œãã¹ã¯çŸ€ã§å»ççšãã¹ã¯çŸ€ã«æ¯ã¹ææã«é«ãããšã瀺ããããç²åã«ããåžè£œãã¹ã¯ã®ééçã¯ã»ãŒ97%ãå»ççšãã¹ã¯ã¯44%ã§ãã£ãã" |
51) ãããŠã£ããã€ã³ãããã®ããŒã¿ã¯ããã«ã¿ãã®ææç©èªãå¹ãé£ã°ãç¶ããŠãã, ãã¬ã€ãºã¡ãã£ã¢, 2021 | "ã€ã³ãããã®è©±-ããã«ã¿ãå€çš®ã®çºçæº-ã¯ã人ã ã«ãããªããããã¯ãææãæ¯é ããŸãæ£ããå¿ èŠæ§ã蚌æããã®ã§ã¯ãªããCOVIDãã¡ã·ãºã ã®çŸåšã®ããããåæãå蚌ãç¶ããŠããŸãã"ãã¹ã¯ã¯ããã§åºãããæ¢ããããšã«å€±æããã®ã§ãã |
52) ãã£ã³ã©ã³ãã®äºæ¬¡èšºçç é¢ã«ãããSARS-CoV-2 Deltaå€ç°åïŒB.1.617.2ïŒã«ããéå£çºçã2021幎5æ, ãããã, 2021 | ãå ±åããã é¢å ææÂ ãã£ã³ã©ã³ãã®HetemÀliãã¯ããã¯ã¯ãã³æ¥çš®ãåããå»çåŸäºè ã®éã§æçç¶ãšç¡çç¶ã®äž¡æ¹ã®ææãèªããããå人é²è·å ·ã®äœ¿çšã«ããããããæçç¶ææè ããäºæ¬¡ææãçºçããããšèгå¯ããŠããŸãã |
53) é«åºŠã«ã¯ã¯ãã³æ¥çš®ãããéå£ã«ãããSARS-CoV-2 Deltaå€ç°åã«ããé¢å éå£çºçãã€ã¹ã©ãšã«ã2021幎7æ2021幎ãã·ããªãã | ã§ã®Â ç é¢çºç ã€ã¹ã©ãšã«ã§è¡ããã調æ»ã§ãShitritãã¯ã2åã¯ã¯ãã³æ¥çš®ãåãã人ãšãã¹ã¯ããã人ã®éã§SARS-CoV-2 Delta variantã®é«ãäŒææ§ãèŠãããããšè¿°ã¹ãŠããã圌ãã¯ããã«ãããã®ããšã¯ãå䜵çã®ãªãå人ã«ã¯ãŸã äºé²å¹æããããšã¯ãããå ç«ã®è¡°ãã瀺åããŠããããšè¿°ã¹ãŠãããããã§ããå人é²è·å ·ã䜿çšããŠããã«ããããããã |
54) 47ã®ç ç©¶ãCOVIDã«å¯Ÿãããã¹ã¯ã®é广ã確èªããããã«32ã®ç ç©¶ãå¥åº·ãžã®æªåœ±é¿ã確èªããŠããŸãã ã©ã€ããµã€ããã¥ãŒã¹ã¹ã¿ããã2021幎 | ãŠã€ã«ã¹ãå°ããããŠããã®ããã«èšèšããã髿§èœã®ãã¹ã¯ä»¥å€ã§ã¯ãã»ãšãã©ã®ãã¹ã¯ãççšããŠããŠã€ã«ã¹ã黿¢ã§ããªãããšãåãã£ãŠãããäžè¬äººãé©åã«ççšãã亀æãæž æãç¶ããã«ã¯ã³ã¹ããããããããŠè€éãªããããã®ç¿æ £ãæ£åœåããç ç©¶ã¯å¿ èŠãªãã£ãã®ã§ããããŸããåžžèçãã€åºç€ç§åŠçãªçç±ãããé·æéã®ãã¹ã¯ççšã¯äžå¥åº·ã§ããããšãçè§£ãããŠããã" |
55) EUAãã¹ã¯ã¯ãŠã€ã«ã¹ææã®æ¡å€§ãæå¶ãã广ããããïŒÂ ãããã2021幎 | ãã¹ã¯ãæå¹ã§ãªãããšã¯ãèšå€§ãªèšŒæ ããæããã§ãã |
56) CDC ã³ãããŠã€ã«ã¹ææè ã®å§åç倿°ããã¹ã¯ãççšããŠãããšã®èª¿æ»çµæãã€ãïŒãã§ãã©ãªã¹ã瀟ã2021幎 | "ç±³åœçŸç 察çã»ã³ã¿ãŒ "ã®Â ã»ããã 9æã«çºè¡šãããããã¹ã¯ããã§ã€ã¹ã«ããŒãCOVID-19ã®æææ¡å€§ãé²ãã®ã«æå¹ã§ãªãããšã瀺ããŠããŸãã"äžè²«ããŠãã¹ã¯ãããŠãã人ãã¡ã«ãããã®å¹æãããããšãããããŸããã |
57) ãã¹ã¯ç ç©¶ã®å€§åã¯ãŽã2021幎ããªã€ã®ãŒããŠã¹ | ããã1ã€ã®ç ç©¶ãé©åãªç ç©¶ã¯ãç¡äœçºåæ¯èŒè©Šéšã§ãããã¹ã¯ãããŠããéå£ã®ææçãšãã¹ã¯ãããŠããªãéå£ã®ææçãæ¯èŒããã®ã§ããããã§ããã¹ã¯éšéã«ãšã£ãŠäºæ ã¯ãã£ãšãã£ãšæªãæ¹åã«é²ãã§ããã圌ãã¯äœã¶æããããŠããã®è«æã®åºçã黿¢ããããšããã ãã³ããŒã¯ç¡äœçºåæ¯èŒè©Šéšãã¹ã¯ã®å¹æã¯ãŒãã§ããããšãçºèŠããã®ã§ãããã®è«æãããããå°å·ããããšã圌ãã¯ããã«äœã¶æããããŠå¿ æ»ã«ãã®ç©ŽãçªãããšããŸããããã®æã圌ãã®ç¡éã®å®å µæãäŒãã£ãŠããã ãã³ã°ã©ãã·ã¥èª¿æ»Â ãã9æäžæ¬ãã€ãã«åœŒããæãã¹ãç»å ŽãããTwitterã®éååã¯ãã¹ãŠããç§åŠããã¹ã¯ã®å¹æã瀺ããŠããããšå®£èšã§ããããã«ãªã£ãã®ã ãèªåãã¡ã®ä¿¡å¿µãæ¯ããããã«ãã©ããªèšŒæ ã§ãæã«å ¥ããããšããããŸããåé¡ã®ç§åŠã®æ²ããæ§è³ªã«èª°ãæ°ãã€ããªãã£ãã®ã ããã®ç ç©¶ã§ã¯ããã¹ã¯ãããéå£ã®è¡æž æç çã10%æžå°ããã«éããããã®å¹æã¯ä¿¡é Œåºéã®ç¯å²å ã«åãŸãã»ã©å°ããããšãåãã£ãããã®ç ç©¶ã®èè ã§ããããã¹ã¯ã®å¹æãå®éã«ã¯ãŒãã§ããå¯èœæ§ãæé€ããããšãã§ããªãã£ãã |
58) ã³ãã¥ããã£ã«ããããã¹ã¯ã®äœ¿çšïŒæåã®æŽæ°, ECDC, 2021 | "ãã§ã€ã¹ãã¹ã¯ã«æå©ãªè³ªã®é«ããšããã³ã¹ã¯ãªãã"ã«åºã¥ããŠã®ã¿äœ¿çšãæšå¥šãããäºé²åå." |
59)Â ææŽãããã¹ã¯ã®ççšãªã©ã®ç©ççãªå¯Ÿçã¯ãåŒåžåšç³»ãŠã€ã«ã¹ã®èå»¶ãæ¢ãããé ããããããã®ã§ããããïŒ, ã³ã¯ã¬ã¢, 2020 | ã7ã€ã®ç ç©¶ã¯å°å瀟äŒã§è¡ããã2ã€ã®ç ç©¶ã¯å»çåŸäºè ã§è¡ãããŸããããã¹ã¯ãççšããªãå Žåãšæ¯èŒããŠããã¹ã¯ãççšããŠããã€ã³ãã«ãšã³ã¶æ§çŸæ£ã«ããã人æ°ã«ã»ãšãã©å·®ã¯ãªãïŒ9ç ç©¶ã3507人ïŒãå®éšå®€æ€æ»ã§ã€ã³ãã«ãšã³ã¶ã確èªããã人æ°ã«å·®ã¯ãªããšæãããŸãïŒ6ç ç©¶ã3005人ïŒã奜ãŸãããªãäœçšã¯ã»ãšãã©å ±åãããŠããŸããããäžå¿«æãªã©ããããŸãã" |
60)Â å ¬è¡ã®é¢åã§ã®å£éŒ»ä¿è·æå¹æ§ã®æ ¹æ ã¯ãªããã£ãŒã / ã«ãã·ã¥ã¿ã€ã³ 2020幎 | "å ¬å ±ã®å Žã§ã®ãã¹ã¯ã®äœ¿çšã¯ãç§åŠçããŒã¿ããªãã ãã«çåãæ®ããå¿ èŠãªäºé²æªçœ®ãèæ ®ããã°ãç é¢ã§ç¥ãããŠããã«ãŒã«ã«åŸã£ãŠããã¹ã¯ã¯å ¬å ±ã®å Žã§ã®ææã®ãªã¹ã¯ãšããèŠãªãããªããã°ãªããªã...ãããåœæ°ããã¹ã¯ãççšããã°ããããå»ççšãã¹ã¯ã§ããããšãããããã³ãã¥ããã£çšãã¹ã¯ã§ããããšãäœããã®å·¥å€«ããªãããŠããããšãææã®ãªã¹ã¯ã¯æœåšçã«é«ãŸãã®ã§ããããRKIãåœéçãªä¿å¥åœå±ã宣åããŠããäºé²çãèæ ®ããã°ããã¹ãŠã®åœå±ããå ¬å ±ã®å Žã§ã¯ãã¹ã¯ãäžåççšãã¹ãã§ã¯ãªããšåœæ°ã«äŒããªããã°ãªããªãã»ã©ã§ãããªããªããããããã¹ãŠã®åžæ°ã®çŸ©åã§ããããšãäœããã®çç±ã§ãããæãåžæ°ãèªçºçã«è² æ ãããã®ã§ããããšããã¹ã¯ãå ¬å ±ã®å Žã§çãšãªãããã害ãšãªãå¯èœæ§ãããããšã«å€ããã¯ãªãããã§ãã" |
61) 米åœã®åäŸåããã¹ã¯æå°ã¯äžçäžå³ãã,  ã¹ã±ã«ãã£ã³ã°, 2021 | ãåäŸã¯é¡ãèŠãå¿ èŠãããããšã¹ã¿ã³ãã©ãŒã倧åŠå»åŠéšææã®ãžã§ã€ã»ãã¿ãã£ãªã¢æ°ã¯The Postã«èªã£ãããã®ç æ°ã¯éåžžã«æªãã®ã§ãèå»¶ãé£ãæ¢ããããã«ã¯ã©ããªææ®µã§ãæ¡çšããªããã°ãªããªãããšããèãæ¹ããããŸãããåŠæ ¡ã§ã®ãã¹ã¯ã¯ã³ã¹ããããããªããšããããã§ã¯ãããŸãããå®éã«ã¯çžåœãªã³ã¹ãããããã®ã§ããã |
62)Â åŠæ ¡ã§ã®å¹Œå ã®ãã¹ã¯ã¯èšèªç¿åŸã«å®³ãåãŒã, ãŠã©ã«ã·ã¥, 2021 | ããŸããé¡ãç¹ã«å£ãèŠãããšã¯ãåäŸãçåŸãåžžã«è¡ã£ãŠããèšèªç¿åŸã«ãšã£ãŠéåžžã«éèŠã§ããããã«ãå£ãèŠãèœåã¯ãã³ãã¥ãã±ãŒã·ã§ã³ã«äžå¯æ¬ ãªã ãã§ãªããè³ã®çºéã«ãäžå¯æ¬ ãªã®ã§ãã" |
63) åã©ãçšãã¹ã¯ã®åé¡ç¹2021幎ããã«ãªãŒ | "ã¯ã¯ãã³ãããŠããªã倧人ã®ããã«ãèŠåŽããŠããåäŸã«ç ç²ã匷ããã®ã¯èåŸ ã " ãã¹ã¯ã¯åäŸã®ã³ããææçãäžããã®ãïŒä¿¡ããããªããããããªããããã®è³ªåã«é¢ããåŸåãç ç©¶ã¯1ä»¶ããèŠã€ãããããã®çµæãçµè«ãåºãŠããªãããããã2é±éåãç±³åœçŸç 察çã»ã³ã¿ãŒã¯ãäºé²æ¥çš®ãåããŠããããªãã«ããããããç±³åœå ã®5600äžäººã®åäŸãšéå°å¹Žã«ãå°å瀟äŒã®ææçã«ãããããé¡ãèŠãããã«ãšå³åœããã®ã§ããããã¹ã¯ã¯å®³ã«ãªããªããããšããããšã§ãåå°ã®åœå±ãåŠæ ¡ããã®ä»ã®å Žæã§ãã¹ã¯ã®ççšã矩åä»ããã®ã§ãããããããããã§ã¯ãããŸããããã¹ã¯ãããŠããŠã倧äžå€«ãªåãããã°ãèŠåŽããŠããåããããè¿èŠã®äººã¯ãã¹ã¯ã§ã¡ã¬ããæã£ãŠèŠãã«ãããªããŸãã(ãã¹ã¯ã¯ããããªã©ã®èãã©ãã«ã®åå ã«ãªãããšããããŸãããã¹ã¯ã®äžå¿«æãããåŠç¿ææ¬²ãæžéããŠããŸãåäŸãããŸãããã¹ã¯ã¯ãåŒæ°æã®æ°éæµæãå¢å ãããè¡äžã®äºé žåççŽ æ¿åºŠãäžæãããããŸãããã¹ã¯ã¯Â ç åäœã®ãã¯ã¿ãŒÂ æ°Žåãå«ãã ããé·æé䜿çšããå Žå". |
64) ãã§ã€ã¹ã«ããŒã®çŸ©åå, ããŒãŽã£ãŒ, 2021 | "ãã§ã€ã¹ã«ããŒã®çŸ©ååãšããã广çã§ãªãçç±" |
65) ãã¹ã¯ã¯å¹æãããã®ãïŒÂ ãšããã³ã¹ã®ã¬ãã¥ãŒ2021幎ãã¢ã³ããŒãœã³ | ãå®éãCDCãè±åœãWHOã®ä»¥åã®æéã¯ããŠã€ã«ã¹ã®æ¡æ£ãé²ããã¹ã¯ã®å¹æã«é¢ããæé«ã®å»åŠçç ç©¶ãšã¯ããã«äžèŽããŠããŸããããã®ç ç©¶ã«ãããšãã¢ã¡ãªã«äººãäœã¶æããã¹ã¯ãã€ããŠããããšã¯ãã»ãšãã©å¥åº·äžã®å©çããããããªãã£ãå¯èœæ§ãé«ããæ°åã³ãããŠã€ã«ã¹ã®æ¡æ£ãé²ãã®ã«é广ã§ãã£ãå¯èœæ§ããããã" |
66) ã»ãšãã©ã®ãã§ã€ã¹ãã¹ã¯ã¯å±å ã§COVID-19ã黿¢ã§ããªãããšã®ç ç©¶çµæãã¢ã³ãã©ãŒç€Ÿã2021幎 | "æ°ããç ç©¶ã«ãããåžè£œãã¹ã¯ã¯åŒæ°ãšã¢ããŸã«ã10%ãããéãããå€ãã®äººãé¡ã«æ£ãããã£ããããã«ããŒãªã³ã°ãè£ çããŠããªãããšãæããã«ãªããŸããã" |
67) ãã§ã€ã¹ãã¹ã¯ãšããã¯ããŠã³ã¯ãªã倱æããã®ã/ãã§ã€ã¹ãã¹ã¯ã®æè¡ãåé¡§ãããã¹ã€ã¹ã»ããªã·ãŒã»ãªãµãŒãã2021幎 | "ãã¹ã¯ã®çŸ©ååãšããã¯ããŠã³ã¯ãç®ã«èŠãã圱é¿ãäžããªãã£ãã" |
68) CDCã¯åŠæ ¡ã§ã®COVIDææèª¿æ»ãçºè¡šããããæãäžå©ãªéšåã®1ã€ã¯é èœãããŠãã2021幎ããã€ãã¹ | ãã¹ã¯ççšã矩åä»ããããåŠæ ¡ã§ã®21%ã®äœãçºççã¯ããã¹ã¯ççšãä»»æã§ãã£ãåŠæ ¡ãšæ¯èŒããŠçµ±èšçã«ææã§ã¯ãªãã£ã...ããšãããŸããç§ã«ã¯äœåäžäººãã®ã¢ã¡ãªã«ã®åäŸãã¡ãåŠæ ¡ã«æ»ããã圌ãã®äž¡èŠªãæ¿æ²»å®¶ã¯ãã©ã®COVID察çãå®éã«å¹æããããã©ã®å¯ŸçããŠã€ã«ã¹ã®æ¡æ£ãææã«ãããã¯æçœã«é ãããããšãªãè匱ãªè¥è ã«äœèšãªè² æ ããããå¯èœæ§ãããããæç¢ºãªèŠéã§ç§åŠçã«å³å¯ã«è°è«ãã矩åãããã»ã»ã»åŠçã®ãã¹ã¯ççšçŸ©åãç¬èªã®å©çã瀺ããªãã£ãããšã¯ãçµæãšããŠéåžžã«è峿·±ãçºèŠãšãããã ããã" |
69) äžçä¿å¥æ©é¢å éšäŒè°COVID-19ïœä»®æ³èšè äŒèŠïœ2020幎3æ30æ¥, 2020 | "ãªãŒã¹ããªã¢ "ã«é¢ãã質åã§ãããªãŒã¹ããªã¢æ¿åºã¯ãåºã«å ¥ãäººå šå¡ã«ãã¹ã¯ãã€ããããããšããæåãæã£ãŠããŸãã以åãããªããšã®èª¬æäŒã§ããã¹ã¯ãäžè¶³ããŠããã®ã§ãäžè¬åžæ°ã¯ãã¹ã¯ãããªãæ¹ããããšçè§£ããŠããŸããããªãŒã¹ããªã¢ã®æ°ãã察çã«ã€ããŠã¯ïŒ...ãªãŒã¹ããªã¢ã®ãã®å¯Ÿçã«ã€ããŠã¯ãç¹ã«æèããŠããŸãããæœåšçã«ãã®ç æ°ãæã£ãŠãã人ããä»ã®äººã«ç æ°ãç§»ããªãããã«ããããšãç®çãšããŠãããšæšæž¬ãããŸããäžè¬çã«WHOã¯ãäžè¬åžæ°ããã¹ã¯ãççšããããšã¯ããã®äººãä»ã®äººã«ç æ°ãç§»ããªãããã«ããããã§ãããšæšå¥šããŠããŸãããã以å€ã®å¥åº·ãªäººãå ¬å ±ã®å Žã§ãã¹ã¯ãççšããããšã¯ãä»ã®ãšããç¹ã«å©ç¹ããªããããäžè¬çã«ã¯æšå¥šããŠããŸããã |
70) ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ææäºé²ã®ããã®ãã§ã€ã¹ãã¹ã¯ïŒã·ã¹ãããã£ãã¯ã¬ãã¥ãŒã«ãŠãªã³ã°ã2010幎 | ãã¬ãã¥ãŒã§ã¯ãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ææãæžããããã®ãã§ã€ã¹ãã¹ã¯ã®å¹æãå¹èœãæ¯æããéããããšããã³ã¹ã匷調ãããŠããããã¬ãã¥ãŒããã©ã®ç ç©¶ããHCWãå°åäœæ°ã®ãããã«ãããŠãããã¹ã¯ççšã«ããå©çã瀺ããŠããªã äžåž¯Â (H)." |
71) å»çåŸäºè ãæ¥æ§åŒåžåšææçããå®ãããã®N95ã¬ã¹ãã¬ãŒã¿ãšãµãŒãžã«ã«ãã¹ã¯ã®æå¹æ§ïŒç³»çµ±çã¬ãã¥ãŒãšã¡ã¿åæã ã¹ãã¹ã2016幎 | "å®éšå®€ç°å¢ã§ã¯N95ã¬ã¹ãã¬ãŒã¿ã¯ãµãŒãžã«ã«ãã¹ã¯ãããä¿è·æ§èœãåªããŠããããã«èŠããããæã ã®ã¡ã¿åæã§ã¯ãèšåºç°å¢ã«ãããŠå»çåŸäºè ãäŒéæ§æ¥æ§åŒåžåšææçããä¿è·ããäžã§N95ã¬ã¹ãã¬ãŒã¿ããµãŒãžã«ã«ãã¹ã¯ãããåªããŠãããã©ãããæç¢ºã«å€æããã«ã¯ããŒã¿ãäžååã§ãã£ã...ã" |
72) å»çåŸäºè ã®åŒåžåšææçã«å¯Ÿãããã¹ã¯ãšã¬ã¹ãã¬ãŒã¿ã®æå¹æ§ãã·ã¹ãããã£ãã¯ã¬ãã¥ãŒãšã¡ã¿ã¢ããªã·ã¹, ãªãã§ããã¥, 2017 | ãæã ã¯ãHCWã®CRIããã³ILIã®ãªã¹ã¯ãäœæžããããã®ææå¯Ÿçã®äžç°ãšããŠãç é¢ç°å¢ã«ãããå»ççšãã¹ã¯ã®æ®éçãªäœ¿çšãæ¯æãã蚌æ ãèŠãã ãããå šäœãšããŠãN95ã¬ã¹ãã¬ãŒã¿ãŒã¯ããé«ãä¿è·å¹æãçºæ®ããããå€åæéäžã®æ®éçãªäœ¿çšã¯ãããäžå¿«ã§ããããåãå ¥ããããå¯èœæ§ãé«ã...æã ã®åæã¯ãSARSã«å¯Ÿããå»ççšãã¹ã¯ãšã¬ã¹ãã¬ãŒã¿ãŒã®æå¹æ§ã確èªãããã®ã§ãããäœ¿ãæšãŠãç¶¿ãçŽè£œã®ãã¹ã¯ã¯æšå¥šãããªããå»ççšãã¹ã¯ã®æå¹æ§ã確èªãããããšã¯ãN95ã¬ã¹ãã¬ãŒã¿ãŒãå ¥æã§ããªãäœè³æºåœãç·æ¥äºæ ã®ç°å¢ã«ãšã£ãŠæ¥µããŠéèŠã§ããããã®ãããªå Žåãé²è·ã®èšŒæ ããªããååãªæ» èãããã«ç¹°ãè¿ã䜿çšãããšç åäœã®ææãä¿é²ããå¯èœæ§ã®ããåžè£œãã¹ã¯ããããäœ¿ãæšãŠã®å»ççšãã¹ã¯ãæãŸãã...pH1N1ã«å¯Ÿããå»ççšãã¹ã¯ãŸãã¯N95åŒåžåšã®æç¢ºãªæçæ§ã¯èªããããªãã£ã...å šäœãšããŠãHCWã«ããããã¹ã¯äœ¿çšã«é¢ããæ¿çãç¥ããã蚌æ ã¯äžååã§ãç ç©¶æ°ãå°ãªãå ±åãã€ã¢ã¹ãçµ±èšæ€åºåãæ¬ åŠããã¡ã§ããã" |
73) å»çåŸäºè ã®ã€ã³ãã«ãšã³ã¶äºé²ã®ããã®N95åŒåžåšãšå»ççšãã¹ã¯ã®æ¯èŒ, ã©ããããã, 2019 | "倿¥ã§ã®N95ã¬ã¹ãã¬ãŒã¿ã®äœ¿çšã¯å»ççšãã¹ã¯ãšæ¯èŒããŠãå®éšå®€ã§ã€ã³ãã«ãšã³ã¶ã確èªãããçã«ææå·®ã¯ãªãã£ãã" |
ã€ã³ãã«ãšã³ã¶ã«å¯ŸããN95ã¬ã¹ãã¬ãŒã¿ãšãµãŒãžã«ã«ãã¹ã¯ã®æå¹æ§ãã·ã¹ãããã£ãã¯ã¬ãã¥ãŒãšã¡ã¿ã¢ããªã·ã¹74) ãã¹ã¯ã¯å¹ããªããCOVID-19 ç€ŸäŒæ¿çã«é¢é£ããç§åŠã®ã¬ãã¥ãŒ, ã©ã³ã³ãŒã, 2020 | N95 ã¬ã¹ãã¬ãŒã¿ã®äœ¿çšã¯ãµãŒãžã«ã«ãã¹ã¯ãšæ¯èŒããŠãå®éšå®€ã§ç¢ºèªãããã€ã³ãã«ãšã³ã¶ã®ãªã¹ã¯ã®äœäžãšé¢é£ããªãããã®ããšãããN95åŒåžåšã¯ãã€ã³ãã«ãšã³ã¶æ£è ããã®çãã®ããæ£è ãšå¯æ¥ã«æ¥è§ŠããŠããªãäžè¬åžæ°ããã€ãªã¹ã¯ã§ãªãå»çã¹ã¿ããã«ã¯æšå¥šãã¹ãã§ã¯ãªãããšã瀺åããããããã¹ã¯ãåŒåžåšã®ççšããäžè¬åžæ°ãå°åäœæ°ã«æçã§ããããšã瀺ãRCTç ç©¶ã¯ãªãããã®ãããªç ç©¶ã¯ãããŸãããäŸå€ããªããåæ§ã«ãå ¬å ±ã®å Žã§ãã¹ã¯ãççšãããšããåºç¯ãªæ¿çã«ããå©çã瀺ãç ç©¶ãååšããªãïŒããã«ã€ããŠã¯åŸè¿°ïŒãããã«ã飿²«ããšã¢ããŸã«ç²åã«å¯Ÿãã鮿åãããããããã¹ã¯ççšã«äœããã®å©çããããšããã°ããµãŒãžã«ã«ãã¹ã¯ãšæ¯èŒããŠã¬ã¹ãã¬ãŒã¿ãŒïŒN95ïŒã®ççšã«ããå€ãã®å©çãããã¯ãã§ãããããã€ãã®å€§èŠæš¡ã¡ã¿ã¢ããªã·ã¹ãšãã¹ãŠã®RCTã«ãããããããçžå¯Ÿçå©çããªãããšã蚌æãããŠããŸãã" |
75) ãã§ã€ã¹ãã¹ã¯ã¯ç é¢ã§ã广ããªãããšãåæ°ä»¶ã®ä¿¡é Œã§ããå»åŠçç ç©¶ã§èšŒæãããŠããïŒïŒÂ ãã¡ãŒã¹ãã³ãã«ã¯ã2020幎 | "ãã¹ã¯ã矩ååããŠããæ»äº¡çã¯ã©ããäžãã£ãŠããªããå±å å€ã§ã®ãã¹ã¯ççšãäžåºŠãåœããŠããªãç±³åœ20å·ã¯ããã¹ã¯ã矩ååããŠãã30å·ãããCOVID-19ã«ããæ»äº¡çãåçã«äœãããã¹ã¯ãããŠããªãå·ã®ã»ãšãã©ã¯ãCOVID-19ã«ããæ»äº¡çã人å£10äžäººããã20人以äžã§ã55人ãè¶ ããå·ã¯ãªããæ»äº¡çã55ããé«ã13å·ã¯ãã¹ãŠããã¹ãŠã®å ¬å ±ã®å Žã§ã®ãã¹ã¯ççšã矩åä»ããŠããå·ã§ãããå®ããŠããªãã®ã§ãã" |
76)Â åŸ æ©çæè¡ã«ãããè¡åŸåµéšææäºé²ã®ããã®æè¡çšãã§ã€ã¹ãã¹ã¯ã®æå¹æ§ã¯ãšããã³ã¹ã«åºã¥ãå»åŠã§æ¯æãããŠããã?ããããªã2009幎 | "éãããç¡äœçºå詊éšãããæè¡çšãã§ã€ã¹ãã¹ã¯ã®ççšããåŸ æ©çæè¡ãåããæ£è ã«æå®³ãæçãã¯ããŸã æç¢ºã«ãªã£ãŠããªãã" |
77) CAPDã«ãããè ¹èçäºé²ïŒãã¹ã¯ããã®ãããªãã®ãïŒÂ ãã£ã®ã¢ãŒã, 2000 | "æ¬ç ç©¶ã¯ãCAPDããã°äº€ææã®ãã§ã€ã¹ãã¹ã¯ã®ã«ãŒãã³çãªäœ¿çšã¯äžèŠã§ãããäžæ¢ããããšãã§ããããšã瀺åããŠããã" |
78)Â äººãšæè¡çšãã¹ã¯ã圱é¿ããæè¡å®€ç°å¢ãªãã¿ãŒã1975幎 | ãæè¡çšãã§ã€ã¹ãã¹ã¯ã®ççšã¯ãæè¡å®€å šäœã®ç°å¢æ±æã«åœ±é¿ãäžãããããããäŒè©±ãåŒåžã«ãã飿£ç©ã®åœ±é¿ãåé¿ããããã«ã®ã¿æ©èœãããæè¡å®€ã®ç°å¢æ±æã®äž»ãªåå ã¯äººã§ããã" |
79)Â æšæºçãªæè¡çšãã¹ã¯ã®æå¹æ§ïŒããã¬ãŒãµãŒç²åããçšããæ€èš, ããšãª, 1980 | "å·å£ã®ç²åæ±æã¯ãã¹ãŠã®å®éšã§å®èšŒãããããããã®ãã§ã€ã¹ãã¹ã¯ã®å€è£ ã«ã¯åŸ®å°çã確èªãããªãã£ãã®ã§ããã¹ã¯ã®çžããæŒãåºããŠå·å£ã«å ¥ã蟌ãã ãã®ãšæãããŸãã" |
80) å¿èã«ããŒãã«æ€æ»æã«å¿ èŠãªãåžœåããã¹ã¯ã®ççšã«ã€ããŠã©ãºã¬ããã1989 | ãçµç®çå·Šå¿ã«ããŒãã«æ²»çãåããæ£è 504人ã®çµéšãããã¹ãã¯ãã£ãã«è©äŸ¡ããè¡è ã®ãã£ããããã¹ã¯ã®ççšãšææççºççãšã®é¢ä¿ãæ¢ã£ãããã£ããããã¹ã¯ã®ççšã«ããããããã©ã®æ£è ã«ãææçã¯èŠãããªãã£ãããããã£ãŠãçµç®çå¿èã«ããŒãã«æ²»çäžã«ãã£ããããã¹ã¯ãççšããå¿ èŠããããšãã蚌æ ã¯èŠãã ããªãã£ãã" |
81) 麻é ç§å»ã¯æè¡å®€ã§ãµãŒãžã«ã«ãã¹ã¯ãççšããå¿ èŠããããïŒæç®ã¬ãã¥ãŒãšãšããã³ã¹ã«åºã¥ãæèšã¹ãããŒã2001 | ã1993幎ã«Leylandã宿œãããã¹ã¯äœ¿çšã«é¢ããã¢ã³ã±ãŒã調æ»ã«ãããšã20%ã®å€ç§å»ãå èŠé¡äœæ¥ã«äœ¿çšãããµãŒãžã«ã«ãã¹ã¯ã廿£ããŠããããšã倿ããã50%æªæºã¯ãå»åŠç ç©¶è©è°äŒãæšå¥šãããã¹ã¯ãççšããŠããªãã£ããåæ°ã®å€ç§å»ããèªåèªèº«ãšæ£è ãå®ãããã«ãã¹ã¯ãççšããŠããããã®ãã¡20%ã¯ãäŒçµ±ããã¹ã¯ãççšããå¯äžã®çç±ã§ããããšãèªããŠããã" |
82) åã©ããã¡ãžã®ãã¹ã¯ã®çŸ©åä»ãã¯ãããŒã¿ã«è£æã¡ããããã®ã§ã¯ãããŸããã ãã¡ãªã¢ã2021幎 | "COVID-19 "ã®ãã³ãããã¯ã¹ã¿ãŒããšéãªããªãããã«2018-19幎ã®ã€ã³ãã«ãšã³ã¶ã·ãŒãºã³ã䜿ãã«ããŠããCDCã¯äŒŒããããªçµµãæããŠããŸããããã¯Â æšå®Â ãã®éãå°å ã®ã€ã³ãã«ãšã³ã¶ã«ããæ»äº¡è æ°ã¯480人ãå ¥é¢è æ°ã¯46,000人ã§ãããCOVID-19ã¯ã幞ããªããšã«ãåã©ãã«ãšã£ãŠããã»ã©èŽåœçãªãã®ã§ã¯ãããŸãããç±³åœå°å ç§åŠäŒã«ãããšã45å·ããã®äºåããŒã¿ã§ã¯Â ã¿ãã COVID-19ã®å°å çäŸã®ãã¡0.00%ãã0.03%ãæ»äº¡ã«è³ã£ããšããããšã§ãããã®æ°åãšCDCã®çºè¡šããæ°åãåããããšÂ ç ç©¶Â ãã€ããªããã¢ãã«ã瀟äŒçè·é¢ãæå®€ã®éå£ãªã©ãåŠçã«å¯Ÿãããã¹ã¯ã®çŸ©åä»ãã¯ãåŠæ ¡ã§ã®COVID-19ã®èå»¶ãé²ãäžã§çµ±èšçã«ææãªå¹æããªãããšãåãã£ãã"èªåãã¡ãå®ãããã«ãåŠçã«ãããã®èŒªãããããããšããäž»åŒµã¯æå³ããªãã |
83) è¥ãåŠçããã¹ãã³ã°ããããšã®åŒå®³ã¯ãå®éã«ãããŸãã ãã©ãµãã2021幎 | ãåŠæ ¡ã§ã®ãã¹ã¯ççšã¯ãã³ãããŠã€ã«ã¹ã®æå¶ã«åœ¹ç«ã€ãšæããããããããŸãããããããšã¯éããŸãããã¹ãã€ã³ã§ã¯ã6æ³ä»¥äžã®åäŸã«ã¯ãã¹ã¯ã䜿çšãããŠããŸããããã§ãããç ç©¶ã®èè ãã¯ããã¹ãŠã®å¹Žéœ¢å±€ã«ããããŠã€ã«ã¹äŒæã®ãªã¹ã¯ã調æ»ãããããããã¹ã¯ã倧ããªå¹æãããããã®ã§ããã°ã5æ³å ã®ææçã¯6æ³å ãããã¯ããã«é«ããªãã¯ãã§ããããã®Â ã瀺ããã®ã§ã¯ãããŸããã.ãã®ä»£ããã«ãæã幌ãåäŸãã¡ã®éã§ã¯äœãã£ãææçãã幎霢ãšãšãã«çå®ã«å¢å ãããããé¡ãèŠã矩åã®ãã幎é·ã®åäŸãã¡ã§ã¯æ¥æ¿ã«äœäžããããšã瀺ãããããã®ããšãããåŠæ ¡ã§ã®ãã¹ã¯ççšã¯å€§ããªå¹æããããããªããããŸã£ãã广ããªãå¯èœæ§ãããããšãããããããããå€ãã®æ¿åºé¢ä¿è ã¯ãããããåºæ¬çãªæ¿çã¯å¥å šã§ãåœæ°ã ãã倱æãããã®ããã«ããã¹ã¯ã®çŸ©åä»ããããã«åŒ·åããããšããã |
84)Â åŠæ ¡ã§ã®ãã¹ã¯ãµã€ãšã³ãã£ãã£ãã¯ã»ã¢ã¡ãªã«ã³èªãå°å æã®COVIDææã«é¢ããå ±åã誀ã2021幎ãè±èª/ACSH | ããã¹ãã³ã°ã¯äœãªã¹ã¯ã§å®äŸ¡ãªä»å ¥ã§ããäºé²æªçœ®ãšããŠãç¹ã«ã¯ã¯ãã³æ¥çš®ãã§ããªãå Žåã«æšå¥šããã®ã§ããã°ãããã¯çŽ æŽãããããšã§ããããããããã¯åœæ°ãç¥ããããŠããããšã§ã¯ãããŸãããããããªãå·ç¥äºã®ãã³ã»ããµã³ãã£ã¹ããããµã¹å·ã®æ¿æ²»å®¶ãã¡ã¯ãç ç©¶ã¯ãã¹ã¯çŸ©ååãæ¯æããªããšèšã£ãŠããããšSciAmã®å°èŠåºãã¯åžãããã«æžããŠãããããããããªããåŠæ ¡ã§ã®äœ¿çšã矩åã¥ããåã«ããã®ä»å ¥ãæå¹ã§ããããšãå®èšŒããŠãã ããããããã§ããªããªããã«ãªãã©ã«ãã¢å€§åŠãµã³ãã©ã³ã·ã¹ã³æ ¡ã®è¡æ¶²è «çåŠè ã§ç«åŠåææã®Vinay Prasadãæžããããšãèªããã°ããã 倧西æŽå²ž2020幎3æäžæ¬ã®æç¹ã§ã¯ãæ³šææ·±ãè¡åããããšã«å察ãã人ã¯ã»ãšãã©ããªãã£ãããããã1幎åè¿ãçµã£ãä»ãç§ãã¡ã¯åã©ããã¡ãšãã®èŠªãã¡ã«å¯ŸããŠããã®åãã«ãã¡ããšçãã矩åãããã®ã§ããåŠæ ¡ã§ã®ãã¹ã¯ã®ã¡ãªããã¯ãã¡ãªãããäžåããïŒ2021å¹Žã®æ£çŽãªçãã¯ãã確ããªããšã¯ããããªãããšããããšã«å€ããã¯ãªãã" |
85) ãã¹ã¯ã¯ãå¹ããªãããå¥åº·ã害ããããäººå£æå¶ã«äœ¿ãããŠããããå»åž«å£, ãã€ã³ãº, 2021 | "ãã¹ã¯ã«é¢ããå¯äžã®ã©ã³ãã 忝èŒç ç©¶ã¯ããã¹ã¯ãå¹ããªãããšã瀺ããŠãã "ãšããã¥ãå士ã¯è©±ãå§ããã圌ã¯ãã¢ã³ãœããŒã»ãã¡ãŠãå士ã®ãé«è²Žãªåãã«èšåãããã¡ãŠãã2020幎3æã®è«æãããæ åºŠãå€ãããããšãæããã«ããã ã³ã³ã¡ã³ã¿ãŒã«ãã®äžã§ããã¹ã¯ççšã®å¿ èŠæ§ãšæå¹æ§ã軜èŠãããã®å¹Žã®åŸåã«ã¯ã¢ã¡ãªã«äººã«ãã¹ã¯ã®äœ¿çšãä¿ããã®ã§ããã圌ã¯ç§ãã¡ã«åãã€ããããã¹ã¯ã¯ãå±å å€ãåãããã»ãšãã©ãã¹ãŠã®å Žé¢ã§åœããåã®ãã®ã«ãªã£ãŠããããããããŒå士ã¯ããèµ·ããŠããéãã£ãšãã¹ã¯ãã€ããŠããããšã®å¹æããå®éã«èª¿ã¹ããç ç©¶ããªããããšã«èšåãããããããè£ä»ããç§åŠã¯ãªããç¹ã«ã24æé365æ¥ãèµ·ããŠããéãã£ãšãã¹ã¯ãã€ããŠããããšããå¥åº·ãä¿é²ãããšããäºå®ãè£ä»ããç§åŠã¯ãªãããšããããŒå士ã¯ä»ãå ããã |
86) ãµãŒãžã«ã«ãã¹ã¯ããã®ãšã¢ããŸã«ééãã§ã³ã1992 | "æéå¹ç "ã ãã§ãªã "ç©ºæ°æµæ "ãèæ ®ãã "ãã£ã«ã¿ãŒå質 "ã®èгç¹ããã¯ã"æéå¹çã®é«ããã¹ã¯ "ãå¿ ããããã¹ããªãã¹ã¯ãšã¯éããŸãããå€ç§çšãã¹ã¯ã®åªäœã¯ãå»çåŸäºè ãåãåºãããæåºããããã现èãé€å»ããã«ã¯ååãããããŸãããããããã®å»çåŸäºè ãæœåšçã«ãããããç åäœãå«ããµããã€ã¯ãã¡ãŒã¿ãµã€ãºã®ãšã¢ããŸã«ãé€å»ããã«ã¯ååã§ã¯ãªããããããŸããã" |
87) CDCãã¹ã¯ççšã矩åä»ããããŠããåŠæ ¡ã¯ããªãã·ã§ã³ã®ããªã·ãŒãæã€åŠæ ¡ãšCOVIDã®ææçã«çµ±èšçã«ææãªå·®ã¯èŠãããªãã£ãã2021幎ããã«ãã£ã¢ã¢ | "CDCã¯ããçåŸã®ãã¹ã¯äœ¿çšçŸ©ååã¯ããã¹ã¯äœ¿çšãä»»æã§ããåŠæ ¡ãšæ¯èŒããŠçµ±èšçã«ææã§ã¯ãªãã£ãããšãã調æ»çµæããå ±åæžã®èŠçŽã«å«ããªãã£ãã" |
88) ãããŠã£ããã€ã³ãããã®ããŒã¿ã¯ããã«ã¿ãã®ææç©èªãå¹ãé£ã°ãç¶ããŠãã2021幎ãããŠãªã«ãŠã£ãã | "ãã«ã¿ "å€çš®ã®çºçæºã§ããã€ã³ãããã®è©±ã¯ã人ã ã«ãããªããããã¯ãææãæ¯é ãäžããå¿ èŠæ§ã蚌æããã©ããããCOVIDãã¡ã·ãºã ã®çŸåšã®ããããåæãå蚌ãç¶ããŠãã...ããããªãéããæã ã¯éåžžã«æå¹ãªããã¯ããŠã³ãšãã¹ã¯ã«æ»ããªããã°ãªããªãã®ã§ãããçŸå®ã«ã¯ãã€ã³ãã®çµéšã¯éã®ããšã蚌æããŠããŸããããªãã¡ã1ïŒãã«ã¿ã¯å€§éšåã匱æ¯åããããã®ã§ãèŽæ»çã¯ã¯ããã«äœããã»ãšãã©ã®äººã«ãšã£ãŠã¯é¢šéªã«è¿ããã®ã§ã2ïŒãã¹ã¯ã¯ããã§ã®åºãããæ¢ããããšãã§ããŸããã§ãã3ïŒåœã¯ãããã3%ã®ã¯ã¯ãã³æ¥çš®ã§çŸ€ãå ç«éçã«è¿ã¥ããŸããã |
89) ã¯ã¯ãã³æ¥çš®ãåããå»çåŸäºè ã«ãããSARS-CoV-2 Delta variantã®äŒæããããã 2021幎ããã£ãŠ | LANCETèªã§ã¯ç¢ºå®çãªããšã¯æžãããŠããªããããã£ã³ã©ã³ããã€ã¹ã©ãšã«ã®é¢å ææã®ããã«ãçè·åž«ãå šå¡ãã¹ã¯ãããŠPPEãªã©ãæã£ãŠããããšãæšæž¬ãããPPEããã¹ã¯ãDeltaã®åºãããæå¶ã§ããªãã£ãããšã瀺ããŠããã |
90) ãµãŒãžã«ã«ãã¹ã¯ããã®ãšã¢ããŸã«ééãŠã£ã«ã±ã1992 | "æéå¹ç "ã ãã§ãªã "ç©ºæ°æµæ "ãèæ ®ãã "ãã£ã«ã¿ãŒå質 "ã®èгç¹ããã¯ã"æéå¹çã®é«ããã¹ã¯ "ãå¿ ããããã¹ããªãã¹ã¯ãšã¯éããŸãããå€ç§çšãã¹ã¯ã®åªäœã¯ãå»çåŸäºè ãåãåºãããæåºããããã现èãé€å»ããã«ã¯ååãããããŸãããããããã®å»çåŸäºè ãæœåšçã«ãããããç åäœãå«ããµããã¯ãã³ãµã€ãºã®ãšã¢ããŸã«ãé€å»ããã«ã¯ååã§ã¯ãªããããããŸããã" |
91)Â æšæºçãªå€ç§çšãã§ã€ã¹ãã¹ã¯ã®æå¹æ§ïŒ"ãã¬ãŒãµãŒç²å "ãçšããæ€èšã¯ã€ãªãŒç€Ÿã1980幎 | ããã¹ãŠã®å®éšã«ãããŠãå·å£ãžã®ç²åæ±æã確èªãããŸããããã¹ã¯ã®å€åŽã«åŸ®å°çã確èªãããªãã£ãã®ã§ããã¹ã¯ã®çžãäŒã£ãŠå·å£ã«å ¥ã蟌ãã ã®ã ããããã¹ã¯ã¯ãããã®ã¢ã®äžã«è£ çããããšã§ããã®ãããªæ±æçµè·¯ãé²ãããšãã§ããŸãã |
92) ãã¹ã¯ã¯ãªã广ããªããäžèŠã§ãæå®³ãªã®ãããšããã³ã¹ã«åºã¥ãç§åŠçãªåæã, ããŒãã³, 2020 | "æ°å幎ã«ãããæé«ã¬ãã«ã®ç§åŠç蚌æ ïŒè€æ°ã®ç¡äœçºåå¯Ÿç §è©Šéšã®ã¡ã¿åæïŒã¯ãå»ççšãã¹ã¯ã¯SAR-CoV-2ãå«ãåŒåžåšç³»ãŠã€ã«ã¹ã®ææäºé²ã«å¹æããªããšå§åçã«çµè«ä»ããŠããŸãã"ãã¹ã¯ã䞻匵ãã人ã ã¯ãäœã¬ãã«ã®èšŒæ ïŒèгå¯çå顧詊éšãã¡ã«ããºã è«ïŒã«é Œã£ãŠããããããããã¹ã¯çŸ©ååã®èšŒæ ã䞻匵ããªã¹ã¯ã«å¯Ÿæã§ããåã¯æã£ãŠããŸãã "ãšè¿°ã¹ãŠããŸãã |
93) å»åž«ããã³å»çé¢ä¿è ãããã«ã®ãŒåœå±ããã³ãã«ã®ãŒã®å šã¡ãã£ã¢ãžã®å ¬éæžç°¡AIERã2020幎 | "å¥åº·ãªäººã®å£è å ãã¹ã¯ã¯ããŠã€ã«ã¹ææã®æ¡å€§ã«å¯ŸããŠå¹æããªã" |
94) ã€ã³ãã«ãšã³ã¶ã«å¯ŸããN95ã¬ã¹ãã¬ãŒã¿ãšãµãŒãžã«ã«ãã¹ã¯ã®æå¹æ§ãã·ã¹ãããã£ãã¯ã¬ãã¥ãŒãšã¡ã¿ã¢ããªã·ã¹, ãã³ã°, 2020 | N95ã¬ã¹ãã¬ãŒã¿ã®äœ¿çšã¯ããµãŒãžã«ã«ãã¹ã¯ãšæ¯èŒããŠãå®éšå®€ã§ç¢ºèªãããã€ã³ãã«ãšã³ã¶ã®ãªã¹ã¯äœäžãšé¢é£ããªãããN95åŒåžåšã¯ãã€ã³ãã«ãšã³ã¶æ£è ãçãæ£è ãšå¯æ¥ã«æ¥è§Šããªãäžè¬åžæ°ããã€ãªã¹ã¯ã§ãªãå»çã¹ã¿ããã«ã¯æšå¥šãã¹ãã§ã¯ãªãããšã瀺åãããã" |
95) COVID-19ã«é¢é£ãããã¹ã¯ã®äœ¿çšã«é¢ããã¢ããã€ã¹, WHO, 2020 | "ãããããã¹ã¯ã®äœ¿çšã ãã§ã¯ååãªä¿è·ãæææºå¯Ÿçãè¡ãããšãã§ãããåŒåžåšç³»ãŠã€ã«ã¹ã®ææãæå¶ããããã«ãä»ã®å人ããã³å°åã¬ãã«ã®å¯Ÿçãæ¡çšããå¿ èŠããããŸãã" |
96) è¶çªåãã¹ã¯ïŒãã£ã20åãªã倧äžå€«ã·ãããŒã»ã¢ãŒãã³ã°ã»ãã©ã«ãçŽã2003幎 | ãä¿å¥åœå±ã¯ããµãŒãžã«ã«ãã¹ã¯ããŠã€ã«ã¹ã«å¯Ÿããæå¹ãªé²åŸ¡çã«ãªããªããããããªããšèŠåããŠãããã·ãããŒå€§åŠææçåŠéšã®ã€ãã³ãã»ã³ãµã«ãææã¯ãããã¹ã¯ã¯ä¹Ÿç¥ããŠããéã ãæå¹ã§ãããããããã®ãããªèŠåããã£ãŠãã人ã ã¯ãã¹ã¯ãè²·ãæ±ããå°å£²æ¥è ã¯éèŠã«è¿œãã€ãã®ã«èŠåŽããŠãããšå ±åããŠããã" |
97) ç ç©¶çµæäœ¿çšæžã¿ãã¹ã¯ã®ççšã¯ããã¹ã¯ãççšããªãå Žåãããå±éºã§ããå¯èœæ§ãããããã€ãã2020幎 ãã¹ã¯ççšãããäžæ°éã«ãããSARS-CoV-2ãšã¢ããŸã«ã®åžå ¥æ§ãšæ²çã«åãŒãåœ±é¿ | ãããµãã¥ãŒã»ãã倧åŠããŒãŠã§ã«æ ¡ãšã«ãªãã©ã«ãã¢ã»ãããã£ã¹ã倧åŠã®ç ç©¶è ã«ãããšã3å±€æ§é ã®ãµãŒãžã«ã«ãã¹ã¯ã¯ã空æ°äžã®ç²åããéããå¹çã65ïŒ ã§ãããšã®ããšã§ãããããããã®å¹æã¯ãäžåºŠäœ¿çšãããš25ïŒ ã«ãŸã§äœäžããã"æ°æ§ãåããããã¹ã¯ãççšããããšã¯ãäœãããªãããã¯åžžã«è¯ãã¯ãã ãšèããã®ã¯èªç¶ãªããšã§ãã"ã ãšãã èè ã§ããJinxiang Xiã¯ã"æã ã®çµæã¯ããã®ä¿¡å¿µã5ãã€ã¯ãã¡ãŒãã«ä»¥äžã®ç²åã«å¯ŸããŠã®ã¿æ£ããã2.5ãã€ã¯ãã¡ãŒãã«ä»¥äžã®åŸ®ç²åã«å¯ŸããŠã¯æ£ãããªãããšã瀺ããŠããŸãã"ãšç¶ããŸããã |
ãã¹ã¯ ãã³ãã¹ | |
1) 米åœã«ãããCOVID-19å°ã蟌ãã®ããã®ãã¹ã¯çŸ©ååãšäœ¿çšå¹æã²ã©ã2021幎 | ãç±³åœçŸç 察çäºé²ã»ã³ã¿ãŒããã³å¥åº·è©äŸ¡ç ç©¶æã®ããŒã¿ãçšããŠãç±³åœæ¬åã«ãããCOVID-19ã®ç·çäŸæ°ããã³ãã¹ã¯äœ¿çšéãç®åºãããè¿é£ã®çŸ©ååãããå·ã®çºè¡æ¥ã®äžå€®å€ãçšããŠã矩ååãããŠããªãå·ã«ããããã¹ã¯çŸ©åååŸã®çäŸå¢å ãæšå®ããã"ç±³åœåå·ã«ããããã¹ã¯çŸ©ååãŸãã¯äœ¿çšãšCOVID-19æææ¡å€§ã®æå¶ãšã®é¢é£ã¯èгå¯ãããªãã£ãã |
2) ãããã®12ã®ã°ã©ãã¯ããã¹ã¯ã®çŸ©åã¯COVIDã忢ããããã«äœãããªãããšã瀺ããŠããŸãã, ã¯ã€ã¹, 2020 | ããã¹ã¯ã¯ãå®å šã«å¯éãããé©åã«è£ çãããé »ç¹ã«äº€æããããŠã€ã«ã¹ãµã€ãºã®ç²åçšã«èšèšããããã£ã«ã¿ãŒãããã°ãããŸãæ©èœããŸãããã®ããããã¹ã¯ã¯å»åŠçãªè§£æ±ºçãšãããããèªä¿¡ã®ããªãã¯ã®ãããªãã®ã ãç§åŠçã§ãªããã¹ã¯ã®äœ¿çšã¯ãç§åŠãšãããããäžäžã®è¿·ä¿¡ã«è¿ãããã®ç©èªã§ã¯ãããæ£è ãæžã£ãããããã¯ãã¹ã¯ãæåããããã ãšèšããŸããããææè ãå¢ããããããã¯ãã¹ã¯ãããå€ãã®ææè ãé²ãããšã«æåããããã ãšèšãããã¹ã¯ãæå¹ã§ããããšã蚌æããã®ã§ã¯ãªããåã«ä»®å®ããŠããã®ã§ãã |
3) ãã¹ã¯ççšçŸ©ååã«ããCCPãŠã€ã«ã¹ææçãäžæãããšã®ç ç©¶çµæ2020幎ããŽã¡ãã¥ã | "æææ¡å€§é²æ¢ "ãç®çãšããé²è·ãã¹ã¯ã®çŸ©åå CCPãŠã€ã«ã¹Â åå ãšãªã COVID-19 ã¯ãããŒã¿ã¢ããªã¹ããã³ã³ãã¥ãŒã¿ç§åŠè ãã¢ã¯ãã¥ã¢ãªãŒãããªãèã®æ ¹ã°ã«ãŒããéå¶ããCOVID-19ããŒã¿ãã¬ã³ãã®ã¯ãªã¢ãªã³ã°ããŠã¹ãRationalGround.comã®å ±åæžã«ãããšããã®æ®åãä¿é²ããããã§ãã" |
4) ãããŠã£ãã50å·ã®å
æ¬çãªåæã§ã¯ããã¹ã¯ã®çŸ©ååã§ãã倧ããªåºãããèŠããã, ããŠã«ãŽã£ãã, 2020 ãžã£ã¹ãã£ã³ã»ããŒã | "æ¿æ²»å®¶ã¯ãã€ãŸã§çµæãç¡èŠãããã ïŒ" "çµæãã¹ã¯ççšçŸ©åã®ããå·ãšãªãå·ããããã¯ããå·ãšãªãå·ã®æéãæ¯èŒãããšããã¹ã¯ççšçŸ©åãæ®åãé ãããããã«åãããšãã蚌æ ã¯å šããããŸããã矩ååã宿œãããå·ã§ã¯ãåèš5907æ¥éã«960äž5256ä»¶ã®COVIDã確èªããã1æ¥ããã10äžäººãããå¹³å27ä»¶ã§ãã£ããå·ããšã®åœä»€ããªãã£ãå ŽåïŒäžåºŠããªãã£ãå·ãããã¹ã¯å·ãåœä»€ãåºããŠããªãã£ãæéãå«ãïŒãåèš5,772æ¥éã§5,781,716ä»¶ã1æ¥ããã10äžäººãããå¹³å17ä»¶ã§ãã£ãã" |
5) CDCã®ãã¹ã¯çŸ©åå調æ»ãè«ç Žããã2021幎ãã¢ã¬ããµã³ã㌠| "ãããã£ãŠãCDCèªèº«ãæè¿åºããçµè«ã æ°åã€ã³ãã«ãšã³ã¶ã«ããããã¹ã¯ãªã©ã®éè¬å察çã¯ãç§åŠçã«ããããã®å¯Ÿçã«é¢ãã14ã®ç¡äœçºåå¯Ÿç §è©ŠéšããåŸããã蚌æ ã¯ãææã«å¯Ÿããå®è³ªçãªå¹æãæ¯æãããã®ã§ã¯ãªãã£ã...ããšèŠåããŠãããããã«ããã®äžã§Â WHOã®2019幎çã¬ã€ãã³ã¹ææžÂ ãã³ãããã¯æã®å»è¬å以å€ã®å ¬è¡è¡ç察çã«ã€ããŠããã§ã€ã¹ãã¹ã¯ã«ã€ããŠãææãæžããã®ã«æå¹ã§ãããšãã蚌æ ã¯ãªã...ããšå ±åãããŠããŸããåæ§ã«ãæè¿è¡ãããäºéç²æ€ãäºéãã¹ã¯ã®ã·ãã¥ã¬ãŒã·ã§ã³ã®çްç®ã§ã¯Â CDCã¯æ¬¡ã®ããã«è¿°ã¹ãŠããŸãã ã¯ã"ãããã®ã·ãã¥ã¬ãŒã·ã§ã³ïŒãã¹ã¯ã®äœ¿çšãæ¯æããïŒã®çµæã¯ãæå¹æ§ãäžè¬åãã¹ãã§ã¯ãªã...ãŸããå®ç°å¢ã§ççšããå Žåã®æå¹æ§ã代衚ãããã®ã§ãããšè§£éãã¹ãã§ã¯ãªã "ãšè¿°ã¹ãŠããŸãã |
6) ãã£ã«ã»ã±ã«ãã³, ãã€ãŒã, 2021 ã¹ãã¯ãã€ã¿ãŒ | ã嬿ã®ããŒã¿ãå«ããå·ã®ãã¹ã¯çŸ©ååãšäœ¿çšã«é¢ããåã®çæ åŠçç ç©¶ããå°å瀟äŒãžã®äŒæçãäœãå Žåãé«ãå ŽåããçäŸã®å¢å ã¯çŸ©ååãšã¯ç¡é¢ä¿ã§ããããã¹ã¯ã®äœ¿çšã¯å€ãç§å¬ã®æ³¢ã«ãããçäŸã®å¢å ãäºæž¬ããªãã£ã". |
7) ãã§ã€ã¹ãã¹ã¯ãšããã¯ããŠã³ã¯ãªã倱æããã®ãSPRã2021幎 | ãææçã¯äž»ã«å£ç¯çã»é¢šåçèŠå ã«ãã£ãŠåŒãèµ·ããããŠãããããã¹ã¯ççšçŸ©åãããã¯ããŠã³ã¯æç¢ºãªåœ±é¿ãåãŒããªãã£ããã |
8) COVID-19ãã¹ã¯ççšçŸ©ååãç é¢è³æºã®æ¶è²»ãšæ»äº¡çã«äžãã圱é¿ã®çã¬ãã«ã§ã®åæã·ã£ãŠã¢ãŒç€Ÿã2021幎 | "ãã¹ã¯ççšçŸ©åã®å®æœã«èµ·å ããCOVID-19éœæ§æ£è ã®äžäººåœããã®æ¥åž°ãæ»äº¡çãç åºãICUç åºã人工åŒåžåšã®å æçã®æžå°ã¯èŠãããªãã£ãã" |
9) ãã¹ã¯ã®çŸ©ååã¯å¿ èŠãªã®ã2021幎ãããªã¹ | ããããããã®åŸã«çºçãã1918幎ã®ã¹ãã€ã³é¢šéªã¯ã现èãããå°ããªç åäœãèå»¶ãããŠã€ã«ã¹æ§ã®ç æ°ã§ããããã¹ã¯ã®æçšæ§ã¯ã¯ããã«äœãããšã倿ãããäŸãã°ã«ãªãã©ã«ãã¢å·ã®ä¿å¥çãÂ å ±åæžã¿Â ãã¹ã¯ã矩åä»ããã¹ããã¯ãã³åžãšçŸ©åä»ããªãã£ããã¹ãã³åžã®æ»äº¡çã«ã»ãšãã©å·®ããªãã£ãããšãããç容垫ãªã©ãªã¹ã¯ã®é«ãäžéšã®è·æ¥ãé€ãããã¹ã¯ã®çŸ©åä»ãã«å察ããããå§åãããRCTã®äžã«ã¯ããã¹ã¯ã®ãããã³ã«ãå®ç§ã«å®ãããšã§ã€ã³ãã«ãšã³ã¶ãäºé²ã§ããããšã瀺åãããã®ãããããã¡ã¿ã¢ããªã·ã¹ã§ã¯ãå šäœãšããŠããã¹ã¯ã«ããäºé²å¹æã¯ã»ãšãã©ãªããšãããŠããã WHOã¬ã€ãã©ã€ã³Â 2019幎ã®ã€ã³ãã«ãšã³ã¶ã«é¢ããèšäºããããã¹ã¯ã®ãæœåšçãªæå¹æ§ã«å¯Ÿããã¡ã«ããºã çãªåŠ¥åœæ§ãã«ãããããããç ç©¶ã§ã¯ã確å®ãªç¢ºç«ã«ã¯å°ããããæå¹æ§ã瀺ããããšè¿°ã¹ãŠããŸãããŸããå¥ã®Â æç®èª¿æ»Â éŠæž¯å€§åŠã®ç ç©¶è ã«ããæèŠã«åæããŠããŸãã2018幎ãŸã§ã«çºè¡šããã10ä»¶ã®RCTã«åºã¥ããµãŒãžã«ã«ãã¹ã¯ã®ã€ã³ãã«ãšã³ã¶ã«å¯Ÿããé²åŸ¡å¹æã®ãã®æè¯ã®æšå®å€ã¯ãããã22ïŒ ã§ããããŒã广ãæé€ããããšã¯ã§ããŸããã§ããã" |
ãã¹ã¯ããŒã | |
1) ã³ããã®åã©ãç ç©¶Co-Kiãå°å ã«ãããå£ãšéŒ»ã®ä¿è·å ·ïŒãã¹ã¯ïŒã«é¢ãããã€ãå šåã察象ãšããã¬ãžã¹ããªã®æåã®çµæã·ã¥ã¯ã«ãã2021幎 | "ãã¹ã¯ã®å¹³åè£ çæéã¯1æ¥270åã§ããããã¹ã¯ççšã«ããé害ã¯ã68%ã®ä¿è·è ããå ±åãããããã®å 容ã¯ãã€ã©ã€ã©ïŒ60%ïŒãé çïŒ53%ïŒãéäžåã®äœäžïŒ50%ïŒãå¹žçŠæã®äœäžïŒ49%ïŒãåŠæ ¡ã»å¹Œçšåãžã®è¡ãæžãïŒ44%ïŒãåŠæ æïŒ42%ïŒåŠç¿é害ïŒ38%ïŒãç æ°ãç²åŽïŒ37%ïŒã§ãã "ãšãããŸãã |
2) åäŸçšãã¹ã¯ããå±éºãªç åäœãæ€åºãããã«ãã¬ã©ã2021幎 | "ãã¹ã¯ã¯çްèãå¯çè«ãçèã§æ±æãããŠããããã®ãã¡3ã€ã¯å±éºãªç åæ§çŽ°èãšèºçãåŒãèµ·ãã现èã§ãã£ã" |
3) ãã¹ã¯ãåœãã®å®å šæ§ãšæ¬åœã®å±éºæ§ 第2åïŒãã¹ã¯ã«ãã埮çç©ãžã®ææŠãããŽã©ã€ã2020/2021 | ãé»è»éå€è 20åã®äœ¿çšæžã¿ãã¹ã¯ãæ€æ»ããçµæã20åäž11åãã10äžå以äžã®çްèãæ€åºãããŸããããŸããã«ããé µæ¯ãæ€åºãããããã®ãã¡3æã¯100äžå以äžã®çްèã³ãããŒãå«ãã§ãã...ãµãŒãžã«ã«ãã¹ã¯ã®å€åŽè¡šé¢ã«ã¯ãç é¢å ã§ã以äžã®åŸ®çç©ãç°å¢äžãããé«ãæ¿åºŠã§ååšããŠããããšã倿ããã现èã§ã¯ãããŠçèå±ïŒ57%ïŒãã·ã¥ãŒãã¢ãã¹å±ïŒ38%ïŒããçèã§ã¯ããã·ãªãŠã å±ïŒ39%ïŒãã¢ã¹ãã«ã®ã«ã¹å±ïŒ31%ïŒãåªå ããŠããã" |
4) 倧æè¡ã«ããããµãŒãžã«ã«ãã¹ã¯ã«ããè±é žçŽ ã®äºåçå ±åãããŒã2008 | "æã ã®èª¿æ»çµæãèæ ®ãããšãè¡è ã®èææ°ã¯å¢å ããSpO2ã¯æåã®1æéåŸã«æžå°ããããã®ããã«SpO2ãæ©æã«å€åããã®ã¯ãé¡é¢ãã¹ã¯ã«ãããã®ããæäœã¹ãã¬ã¹ã«ãããã®ããã©ã¡ããã§ãããããã®ã¬ãã«ã®éåžžã«å°ããªé£œååºŠã®æžå°ã¯ã倧ããªPaO2ã®æžå°ãåæ ããŠããã®ã§ãæã ã®çºèŠã¯ãå»çåŸäºè ãå€ç§å»ã«ãšã£ãŠèšåºç䟡å€ããããããããŸããã" |
5) ãã¹ã¯ã®çŸ©ååã¯ãåäŸã®æ ç·ãç¥èœã®çºéã«åœ±é¿ãäžããå¯èœæ§ããããŸãã2020幎ãã®ãªã¹ | "ãã®å¹æãããã®ããªãã®ããã¯ã£ãããšããããšã¯ããããªããšããããšã§ããããããç§ãã¡ãç¥ã£ãŠããã®ã¯ãåã©ããã¡ãç¹ã«å¹Œå æã«ã¯ã倧人ãåšå²ã®äººã ããåšãã®ç¶æ³ãæãåãããã«ãé¡å šäœã®äžéšãšããŠå£ã䜿ããææ ã衚çŸããŠãããšããããšã§ãããŸããèšèã®çºéã«ãé¢ãã£ãŠããŸãã乳幌å ãèããŠã¿ããšãçžæãšæ¥ãããšãã¯å£ã®äžéšã䜿ã£ãŠããŸãããã圌ãã¯ããªãã®è¡šæ ã«èå³ãããã®ã§ãããã®é¡ã®äžéšãé ãããŠãããšèãããšããã®åœ±é¿ãããå¯èœæ§ããããŸãããããããä»ã¯æ¬åœã«åäŸããªãã®ã§ããããŸãããç§ãã¡ãçåã«æãã®ã¯ãããã圹å²ãæããå¯èœæ§ãããã®ãããããŠãåã©ãã®çºéã«åœ±é¿ãäžããã®ã§ããã°ãã©ãããã°ãããæ¢ããããšãã§ããã®ããšããããšã§ãã" |
6) å»çåŸäºè ã®é çãšN95ãã¹ã¯ãªã ã2006幎 | "å»çåŸäºè ã¯ãN95ãã§ã€ã¹ãã¹ã¯ã®äœ¿çšåŸã«é çãçºçããå¯èœæ§ãããã" |
7) SARS-CoV-2ã®ææãšæé²ãäœæžããããã®åžè£œãã¹ã¯ãšå»çåŠçœ®çšãã¹ã¯ã®æå€§éã®é©åæ§ã2021幎ãã«ãã¯ã¹ã2021幎 | ãäºéãã¹ã¯ãçµã³ç®ãã¿ãã¯ã®äœ¿çšã¯ããã¹ã¯ã®ãã£ããæãæé©åããçºçæºå¯Ÿçãççšè ã®ä¿è·ã®ããã®ãã¹ã¯æ§èœãé«ããããšãã§ããå€ãã®éžæè¢ã®ãã¡ã®2ã€ã§ãããäºéãã¹ã¯ã¯ççšè ã«ãã£ãŠã¯åŒåžã劚ãããåšèŸºèŠéã劚ãããããå Žåããããçµã³ç®ãã¿ãã¯ã¯ãé¡ã®å€§ããªäººã®éŒ»ãšå£ã®äž¡æ¹ãå®å šã«ã«ããŒããªããªãããã«ãã¹ã¯åœ¢ç¶ãå€åããå ŽåããããŸãã"ãšãããŸãã |
8) COVID-19æä»£ã®ãã§ã€ã¹ãã¹ã¯ãå¥åº·ä»®èª¬, ãŽã¡ã€ã³ã»ã«ãã€ã , 2021 | ããã§ã€ã¹ãã¹ã¯ã®ççšã¯ãçççã»å¿ççã«å€§ããªæªåœ±é¿ãåãŒãããšãå®èšŒãããŠããŸããäœé žçŽ ãé«çé žãæ¯åããé žæ§åºŠã®äžæã𿝿§ãææãšã¹ãã¬ã¹åå¿ã®æŽ»æ§åãã¹ãã¬ã¹ãã«ã¢ã³ã®äžæãå ç«æå¶ãç²åŽãé çãèªç¥èœåã®äœäžããŠã€ã«ã¹ãææçã®çŽ å ãæ ¢æ§ã¹ãã¬ã¹ãäžå®ã鬱ãªã©ã§ãã" |
9) ãã¹ã¯ãççšãããšãããã3åéã§åã©ããã¡ãå±éºãªã¬ãã«ã®äºé žåççŽ ã«æé²ãããããšã倿2021幎 ã·ã£ããŒã³/ãã€ãªãŒã¡ãŒã« | "ãšãŒãããã®ç ç©¶ã§ã¯ãæ°åéã ããã¹ã¯ãããåäŸãã¡ãå±éºãªã¬ãã«ã®äºé žåççŽ ã«ãããããå¯èœæ§ãããããšãããã£ã...45人ã®åäŸãã¡ãå¥åº·ãªã¬ãã«ã®3åãã12åã®äºé žåççŽ ã«ããããã "ãšããã |
10) äœäººã®åã©ããæ»ãªãªããã°ãªããªãã®ãã ã·ã«ãããŒã2020幎 | "芪ã¯ãã€ãŸã§ãåœããã§åäŸã«å€§ããªå®³ãäžããä»®é¢ããã¶ãç¶ããã®ã ããã ãšãªãã¯ã»ãããå士 ãã¹ã¯ã®é·æéã®äœ¿çšã«ããèºã®çŽ°èææã§æ£è ã®4æ³ã®åäŸãæ»ã«ãããåŸãã»ã³ãã«ã€ã¹ã«äœã圌ã¯ãã¿ããªã«å ±æããŠã»ãããšããæŽèšã®ãããªãæ®ãããã«æéãå²ããŸããã |
11) ãã¹ã¯ççšã«ãããçŽ°èæ§èºçãå¢å ããŠããããšå»åŠå士ãèŠéã鳎ãã, ããŒãã³, 2021 | "é¡ã®çºç¹ãçèææçãçŽ°èææçã®æ£è ã蚺ãŠããŸããäžçäžã®ååããå¯ããããå ±åã«ãããšãçŽ°èæ§èºçãå¢å ããŠããããã§ãããªãããšãããšãèšç·ŽãåããŠããªãäžè¬åžæ°ãå»ççšãã¹ã¯ãç¹°ãè¿ãççšããéæ» èçãªæ¹æ³ã§... æ±æãããŠããããã§ããè»ã®ã·ãŒããããããã¯ãã©ãŒããããã±ãããããã«ãŠã³ã¿ãŒãããã¹ã¯ãåŒã£åŒµãåºããæ¯åæ°é®®ã§æ» èããããã¹ã¯ãççšããªããã°ãªããªãã®ã«ããããåè£ çããŠããã®ã§ãã |
12) å»åž«ããã³å»çé¢ä¿è ãããã«ã®ãŒåœå±ããã³ãã«ã®ãŒã®å šã¡ãã£ã¢ãžã®å ¬éæžç°¡AIERã2020幎 | "ãã¹ã¯ççš "ã«å¯äœçšããªãããã§ã¯ãããŸãããé žçŽ æ¬ ä¹çïŒé çãåãæ°ãåŠæ æãéäžåäœäžïŒãããªãæ©ãèµ·ãããé«å±±ç ãšåããããªå¹æãåŸãããŸããç§ãã¡ã¯æ¯æ¥ããã¹ã¯ççšã«ããé çãå¯éŒ»è çŸæ£ãåŒåžåšçŸæ£ãéåŒåžã蚎ããæ£è ãç®ã®åœããã«ããŠããŸããããã«ãèç©ãããäºé žåççŽ ã¯çäœã®æå®³ãªé žæ§åãæããç§ãã¡ã®å ç«ã«åœ±é¿ãåãŒããŸããå°éå®¶ã®äžã«ã¯ããã¹ã¯ã®äžé©åãªäœ¿çšã®å ŽåããŠã€ã«ã¹ã®ææãå¢å ãããšèŠåãã人ãããã»ã©ã§ãã" |
13) ã³ãã19ã®ããã®ãã§ã€ã¹ã«ããŒïŒå»çä»å ¥ãã瀟äŒçå®è·µãž, Peters, 2020 | "çŸæç¹ã§ã¯ãCovid19ãå«ãåŒåžåšç³»ãŠã€ã«ã¹ã®ææäºé²ã®ããã«ãå°åã®å¥åº·ãªäººãžã®ãŠãããŒãµã«ãã¹ã¯ã®æå¹æ§ã«é¢ããçŽæ¥çãªèšŒæ ïŒCovid19ã«é¢ããç ç©¶ããã³å°åã®å¥åº·ãªäººã§ã®ç ç©¶ïŒã¯ãããŸãããå»ççšãã§ã€ã¹ãã¹ã¯ã®å€åŽã«ä»çãããŠã€ã«ã¹ã现èã«ããäžæ°éã®æ±æã¯ãããã€ãã®ç é¢ã§æ€åºãããŠããŸãããŸããå¥ã®ç ç©¶ã§ã¯ã湿ã£ããã¹ã¯ã¯ïŒæçç©è³ªèæ§ã®ïŒçްèãçèã®æž©åºãšãªããç²èã®ãŠã€ã«ã¹å ç«åãäœäžãããããšãåãã£ãŠããŸãããã®ç ç©¶ã¯ãäžåºŠäœ¿çšãæ°æéã§äº€æããå»ççš/æè¡çšãã¹ã¯ïŒèªå®¶è£œç¶¿ãã¹ã¯ã®ä»£ããïŒã®äœ¿çšãæå±ããŠããŸãã" |
14) ã³ãã19屿©ã®éãåœæ°ã«æäŸãããã§ã€ã¹ãã¹ã¯, ã©ããã¡ãªãŒã, 2020 | "ãã§ã«èªããããŠããå¯äœçšã®å¯èœæ§ã¯2ã€ã(1) ãã§ã€ã¹ãã¹ã¯ã®ççšã¯èª€ã£ãå®å¿æãäžãã瀟äŒçè·é¢ã®åãæ¹ãææŽããªã©ãä»ã®ææå¯Ÿçãžã®ã³ã³ãã©ã€ã¢ã³ã¹ãäœäžãããå¯èœæ§ãããã(ãã¹ã¯ã®äžé©åãªäœ¿çšïŒãã¹ã¯ã«è§Šããªããäœ¿ãæšãŠãã¹ã¯ãé »ç¹ã«äº€æããã宿çã«æŽæµãããæ£ãã廿£ãããªã©ã®ç®¡ççããšããªããšãæ¬äººãåšå²ã®ãªã¹ã¯ãé«ããå¯èœæ§ãããããã®ä»ãèæ ®ããªããã°ãªããªãæœåšçãªå¯äœçšã¯ä»¥äžã®éãã§ãã(3ïŒãã¹ã¯ççšè å士ã®äŒè©±ã®è³ªãé³éãèããäœäžããç¡æèã«æ¥è¿ããå¯èœæ§ãããããã®å¯äœçšã¯ã1.ã®å¯äœçšã«å¯ŸåŠããããã®èšç·Žãå¿ èŠã§ãããããå°é£ãªå ŽåããããŸãã(4) ãã¹ã¯ãããŠãããšãåãæ¯ãç®ã«å ¥ã£ãŠããŸãããããäžå¿«æãçã¿ãç®ãè§Šããããªãè¡åã«é§ããããæãæ±ããŠãããšãèªåèªèº«ã«ææããŠããŸãã" |
15) ç é¢å å»çåŸäºè ã䜿çšããå»ççšãã¹ã¯ã®å€é¢ã«ãããåŒåžåšç³»ãŠã€ã«ã¹ã®æ±æã«ã€ããŠ, Chughtai, 2019 | "äœ¿çšæžã¿å»ççšãã¹ã¯ã®å€é¢ã«ä»çããåŒåžåšç³»ç åäœã¯ãèªå·±æ±æã«ã€ãªããå¯èœæ§ããããŸãããã®ãªã¹ã¯ã¯ããã¹ã¯ã®äœ¿çšæéãé·ãã»ã©ïŒ6æé以äžïŒããŸãèšåºæ¥è§Šçãé«ãã»ã©é«ããªããŸãããã¹ã¯ã®äœ¿çšæéã«é¢ãããããã³ã«ã¯ãé£ç¶äœ¿çšã®æé·æéãèŠå®ããæ¥è§Šçã®é«ãç°å¢ã§ã®æå°ãæ€èšãã¹ãã§ããã" |
16) æ°åã€ã³ãã«ãšã³ã¶æµè¡æã®ãã¹ã¯ã®åå©çšæ§ãã€ã©ãŒã«ã2006 | ãå§å¡äŒã¯ãåãåã£ããã¹ãŠã®èšŒèšãšãã®ä»ã®æ å ±ãèæ ®ããçµæããããã®æ©åšã逿ãã人ã ãå®å šã«è€æ°å䜿çšã§ããããã«ããç°¡åã§ä¿¡é Œã§ããæ¹æ³ã¯ãçŸåšã®ãšããååšããªããšçµè«ä»ããŸããããããã®æ©åšãã€ã³ãã«ãšã³ã¶ã«å¯ŸããŠã©ã®çšåºŠæå¹ã§ãããã«ã€ããŠã¯ãååäœ¿çšæã§ãããå©çšå¯èœãªããŒã¿ã¯æ¯èŒçéãããŠããŸãããŸããã©ããªã«åªããåŒåžåšããã¹ã¯ã§ããäœ¿ãæ¹ã誀ããšã人ãå®ãããšã¯ã§ããŸãããã€ã³ãã«ãšã³ã¶ãã©ã®ããã«åºãããã«ã€ããŠã®çè§£ãæ·±ããããåªãããã¹ã¯ãåŒåžè£ 眮ãéçºãããããã®é€æã容æã«ããããã«ãçžåœãªç ç©¶ãè¡ãå¿ èŠããããŸããæåŸã«ããã§ã€ã¹ã«ããŒã®äœ¿çšã¯ããã³ãããã¯ãé ããããæ¢ãããããããã«å¿ èŠãšãªãå€ãã®æŠç¥ã®äžã€ã«éããã人ã ã¯ãã¹ã¯ãåŒåžåšãæã£ãŠãããããšãã£ãŠãã€ã³ãã«ãšã³ã¶ã«ããããããªã¹ã¯ãé«ãããããªæŽ»åãããŠã¯ãªããªãã" |
17) åŒåžãå³ãäŒè©±ã«ããåŒåžåšç³»ãŠã£ã«ã¹ã®åŒæ°, ã¹ãã«ã¶ãŒãã¬ãŒã, 2009 | ãæ°åãã¹ã¯ãè£ çãã50åã®è¢«éšè ã®å³ãäŒè©±ãåŒåžã«ãã£ãŠçºçããåŒæ°ãšã¢ããŸã«ããµã³ããªã³ã°ãã9çš®é¡ã®åŒåžåšç³»ãŠã€ã«ã¹ãPCRæ³ã§åæããŸããããŸããã©ã€ããŠã€ã«ã¹ãPCRã§éœæ§ãšãªã£ã10åã®è¢«éšè ã®åŒæ°ãµã³ãã«ã«ã€ããŠã现èå¹é€ã«ããæ€æ»ãè¡ã£ããšãããã©ã€ããŠã€ã«ã¹ãæ€åºãããã50人ã®ãã¡ãäžæ°éçã®çç¶ããã£ã33人ã®ãã¡ã21人ã¯å°ãªããšã1ã€ã®ãŠã€ã«ã¹ãPCRã§æ€åºãããç¡çç¶ã®17人ã®ãã¡ã4人ã¯PCRã§ãŠã€ã«ã¹ãæ€åºãããããã®çµæïŒã©ã€ããŠã€ã«ã¹ã19åïŒã€ã³ãã«ãšã³ã¶ã4åïŒãã©ã€ã³ãã«ãšã³ã¶ã2åïŒããã¡ã¿ãã¥ãŒã¢ãŠã€ã«ã¹ã1åã§æ€åºãããïŒãŸãïŒ2åãéè€ææããŠããïŒéŒ»ç²æ¶²ããŠã€ã«ã¹éœæ§ã§ãã£ã25åã®ãã¡ïŒåŒåžã§12åïŒäŒè©±ã§8åïŒå³ã§2åããåãåã®ãŠã€ã«ã¹ãæ€åºããïŒããã«ïŒéŒ»ç²æ¶²ããŠã€ã«ã¹éœæ§ã§ãã£ã25åã®ãã¡ïŒåŒåžã§1åïŒäŒè©±ã§1åïŒå³ã§2åããåãåã®ãŠã€ã«ã¹ãæ€åºãããïŒ10人ã®è¢«éšè ã®åŒæ°ãµã³ãã«ã®ãµãã»ããã§å¹é€æ€æ»ãè¡ã£ããšããã2人ããæææ§ã©ã€ããŠã€ã«ã¹ãæ€åºãããã" |
18) [ãµãŒãžã«ã«ãã¹ã¯ã®6åéæ©è¡è·é¢ãžã®åœ±é¿]ãæ¬äººã2018幎 | "ãµãŒãžã«ã«ãã¹ã¯ã®è£ çã¯æ©è¡è·é¢ã«åœ±é¿ãäžããã«åŒåžå°é£ãææã«èšåºçã«ä¿®æ£ãã" |
19) ä¿è·ãã¹ã¯ã¯åçºåãäœäžããããµã€ãšã³ã¹ORFã2020幎 | "ãã€ãã®ç ç©¶è ãã¡ã¯ããµãŒãžã«ã«ãã¹ã¯ãšãäž»ã«å»çåŸäºè ã䜿çšããFFP2ãšåŒã°ãããã¹ã¯ã®2çš®é¡ã®ãã§ã€ã¹ãã¹ã¯ãç ç©¶ã«äœ¿çšããŸãããæž¬å®ã¯ãæ£è ãŸãã¯è¢«æ€è ã鿢èªè»¢è»ïŒãããããšã«ãŽã¡ãŒã¿ãŒïŒãŸãã¯ãã¬ãããã«ã§èº«äœãåããã¹ãããšã«ãŽã¡ãŒã¿ãŒã«ãã£ãŠè¡ãããã被éšè ã¯ãã¹ã¯ãªãããµãŒãžã«ã«ãã¹ã¯ãFFP2ãã¹ã¯ãè£ çããŠæ€æ»ãããããã¹ã¯ã¯åŒåžã劚ããç¹ã«æ¯ãåãåºããšãã®ç©ºæ°ã®éãšé床ãæå€§ã«ããŸãããšã«ãŽã¡ãŒã¿ãŒã§å¯èœãªæå€§åã¯èããæžå°ããã |
20)Â äºæ³ä»¥äžã«äžå¥åº·ãªãã¹ã¯ã®ççš, ã³ããã¢é·ç§», 2020 | "ãã€ã¯ããã©ã¹ããã¯ãå«ã¿ã廿£ç©åé¡ãæªåããã... "ãããã®å€ãã¯ããªãšã¹ãã«ã§äœãããŠããã®ã§ããã€ã¯ããã©ã¹ããã¯ã®åé¡ãããã®ã§ãããã§ã€ã¹ãã¹ã¯ã®å€ãã¯ãå¡©çŽ ååç©ãå«ãããªãšã¹ãã«ã䜿çšããŠããããšã§ãããã"ãã¹ã¯ãé¡ã®åã«ããŠããã°ãåœç¶ãã€ã¯ããã©ã¹ããã¯ãçŽæ¥åžã蟌ã¿ãŸããããããã®ç©è³ªã¯ç¥çµç³»ã«çŽæ¥å ¥ãã®ã§ã飲ã¿èŸŒãã å Žåããããã£ã𿿝ã§ãã"ãã©ãŠã³ã¬ãŒãã¯ç¶ããŸãã |
21) ãã¹ãã³ã°ã»ãã«ãã¬ã³æ²åçã§éç§åŠçããããŠæå®³ãªãã®2021幎ãã¢ã¬ããµã³ã㌠| ãåã©ããã¡ãSARS-CoV-2ã容æã«ç²åŸããããšã¯ãªãïŒãªã¹ã¯ã¯éåžžã«äœãïŒãä»ã®åã©ããã¡ãæåž«ã«ææãããããå®¶åºã§ä¿è·è ãä»ã®äººã«å±å®³ãå ãããããããšããªãããããå®èª¬ã§ãããåäŸãCovidãŠã€ã«ã¹ã«ææããå Žåãéçåãããæ»äº¡ãããããããšã¯éåžžã«çšã§ããããã¹ãã³ã°ã¯ã倧人ãšåãããã«ãåã©ãã«ã害ãåãŒãå¯èœæ§ããããŸããããããè²»çšäŸ¿çåæã¯å€§äººãšåã©ããç¹ã«å¹Œãåã©ãã§ã¯å šãç°ãªãã倧人ã®åæãã©ãã§ãããã³ãã19ã®èå»¶ãé²ãããã«åäŸã«ãã¹ã¯ççšã矩åä»ããã¹ãã§ã¯ãªãã ããããã¡ããããŒããªã¹ã¯ã¯éæã§ããªãããã¹ã¯ãã¯ã¯ãã³ãæ²»çè¬ãè·é¢ã®åãæ¹ããã®ä»å»åŠãéçºãããã®ãæ¿åºæ©é¢ã課ããã®ã®æç¡ã«ãããããã§ããã |
22) ãã¹ã¯ã®å±éºæ§2021幎ãã¢ã¬ããµã³ã㌠| ããã¯ãCovid-19ã®å€§æµè¡ã«ãã£ãŠç§ãã¡ã®æ¥åžžç掻ã®äžéšãšãªã£ããã¹ã¯ïŒå€ç§çšãäžå¿ãšãã倧éçç£åïŒã®å¡©çŽ ãããªãšã¹ãã«ããã€ã¯ããã©ã¹ããã¯ã®æåãããããæœåšçãªå±éºæ§ã§ããããæ¿åºã®èª¬åŸåã®ããæ¹ã ã¯ããã®èšŽãã«è³ãåŸããŠãã ãããããé¡ãããŸããç§ãã¡ã¯ãåœæ°ã®ãªã¹ã¯ãæžããããã«å¿ èŠãªæ±ºå®ããªãããããšãæãã§ããŸãã |
23) 13æ³ã®ãã¹ã¯ççšè ãäžå¯è§£ãªçç±ã§æ»äº¡, ã³ããé·ç§», 2020 | "ãã®äºä»¶ã¯ããã€ãã§ã¯äºé žåççŽ ã«ããäžæ¯ã®å¯èœæ§ã«ã€ããŠæ¶æž¬ãåŒãã§ããã ãã§ã¯ãªãããªããªãããã®åŠçã¯ãã³ããã®é²è·ãã¹ã¯ãããŠãããšãã«çªç¶åããå°ãããŠããç é¢ã§æ»äº¡ããããšWochenblick.Editor's Reviewã¯æžããŠããã®ã§ãããå°å¥³ã®æ»åŸ3é±éè¿ããã£ãŠãæ»å ãäŒããããªããšããã®ã¯ã確ãã«ç°åžžã§ããã空æ°äžã®äºé žåççŽ ã®å«æéã¯ãéåžž0.04ïŒ çšåºŠã§ããã4ããŒã»ã³ãã®å²åãããéçé žãããªãã¡çé žã¬ã¹äžæ¯ã®æåã®çç¶ãçŸããã20ïŒ ä»¥äžã«ãªããšãåœã«ããããçé žã¬ã¹äžæ¯ãèµ·ããå±éºæ§ããããŸããããããããã¯äœããã®ã¢ã©ãŒã ä¿¡å·ããªãããã§ã¯ãããŸãããå»çããŒã¿ã«ãµã€ããnetdoktorãã«ãããšããçºæ±ãåŒåžã®å éãå¿æã®å éãé çãæ··ä¹±ãæèåªå€±ããªã©ãããããã§ãããããã£ãŠãå°å¥³ã®æèåªå€±ã¯ããã®ãããªäžæ¯ã®å åã§ããå¯èœæ§ãããã" |
24) çåŸã®æ»äº¡äºæ ã«ãããäžåœã®åŠæ ¡ã§ã¯ãã¹ã¯ã®ã«ãŒã«ã倿Žã«ã¯ãããã¯ã2020幎 | ã4æã«å ¥ããæµæ±çãæ²³åçãæ¹åçã§äœè²ã®ææ¥äžã«ã©ã³ãã³ã°äžã®çåŸãå¿èçªç¶æ»ïŒSCDïŒã«é¥ãã±ãŒã¹ã3ä»¶å ±åããããå京æ©å ±ã¯ã3人ã®çåŸãæ»äº¡æã«ãã¹ã¯ãããŠããããšãææããçåŸã®ãã¹ã¯ççšã«é¢ããæ ¡åããããæ¹å€çãªè°è«ã«ç«ãã€ããã" |
25) ãã¬ã€ããã¯ãã§ã€ã¹ãã¹ã¯ã¯å¥åº·ãªäººã«æ·±å»ãªå±éºããããã, 2020 | ããã¹ã¯ã®äœ¿çšã«é¢ããç§åŠçãªè£ä»ãã«ã€ããŠã¯ãæè¿ãæç®ãæ éã«èª¿æ»ãã17ã®åªããç ç©¶ãåæããçµæããã©ã®ç ç©¶ãããã¹ã¯/åŒåžåšã®äœ¿çšãšã€ã³ãã«ãšã³ã¶ææã«å¯Ÿããé²åŸ¡ãšã®éã«æ±ºå®çãªé¢ä¿ã確ç«ããŠããªãããšçµè«ã¥ããŠããŸãã1  åžè£œãã¹ã¯ãšN95ãã¹ã¯ã®ã©ã¡ããCOVID-19ãŠã€ã«ã¹ã®ææã«å¹æãããã®ãã蚌æããç ç©¶ã¯è¡ãããŠããªãããšã念é ã«çœ®ããŠãããŠãã ããããããã£ãŠãæšå¥šããå Žåã¯ãã€ã³ãã«ãšã³ã¶ã»ãŠã€ã«ã¹ã®ææã«é¢ããç ç©¶ã«åºã¥ããŠè¡ãå¿ èŠããããŸãããããŠãã芧ããã ããããã«ãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®ææãæå¶ãã广ã«ã€ããŠæ±ºå®çãªèšŒæ ã¯ãªãã®ã§ãã" |
26) ãã¹ã¯ã®å¿ èŠæ§ã¯ãæ·±å»ãªç²Ÿç¥çãã¡ãŒãžãšå ç«åã®äœäžããããããã®ã§ã, ã³ããã¢ã»ãã©ã³ãžã·ã§ã³, 2020 | "å®éããã¹ã¯ã¯ãåºçŸããæ»ææ§ãä»ããŠåŒ·ã粟ç¥ã»ææ
çãªã¹ãã¬ã¹åå¿ãåŒãèµ·ããå¯èœæ§ããããããã¯ã¹ãã¬ã¹ã®åŸéºçã®çšåºŠãšææã«çžé¢ããŠãããã®ã§ãã ãã«ãŒãµã®æèŠã¯ã圌女ã ãã§ã¯ãããŸãããäœäººãã®å¿çåŠè ããã¹ã¯ã®åé¡ã«åãçµã¿ããã®ã»ãšãã©ã壿» çãªçµæã«çµãã£ãŠããããã«ãŒãµã«ããã°ãç¡èŠããããšã¯èŽåœçã§ããã" |
27)Â æ«æè äžå šæ£è ã«ãããSARSäºé²ã®ããã®è¡æ¶²éææã®N95ãã¹ã¯ççšãåãŒãççç圱é¿ã«ã€ããŠè±ç, 2004 | "HDäžã«4æéN95ãã¹ã¯ãè£ çãããšãESRDæ£è ã®PaO2ãææã«äœäžããåŒåžåšç³»ã®æªåœ±é¿ãå¢å ãã" |
28) å£ãšéŒ»ãèŠããã¹ã¯ã¯ãæ¥åžžç掻ã§å¥œãŸãããªãå¯äœçšããªããæœåšçãªå±éºæ§ããªãã®ã§ããããïŒÂ ãã·ãšãªã³ã¹ããŒ, 2021 | ããã¹ã¯ççšè ã®åŒåžççã®å€åã客芳çã«è©äŸ¡ããO.2 äœäžãšç²åŽïŒp<0.05ïŒãåŒåžé害ãšOâã®ã¯ã©ã¹ã¿ãŒçå ±èµ·ãèŠãããã2 ããããïŒ67%ïŒãN95ãã¹ã¯ãCO2 ã©ã€ãºïŒ82%ïŒãN95ãã¹ã¯ãO2 äœäžïŒ72%ïŒãN95ãã¹ã¯ãšé çïŒ60%ïŒãåŒåžéå®³ãšæž©åºŠäžæïŒ88%ïŒãããã«ãã¹ã¯äžã®æž©åºŠäžæãšæ¹¿æ°ïŒ100%ïŒãªã©ãèŠããããäžè¬äººã«ããé·æéã®ãã¹ã¯ççšã¯ãå€ãã®å»çåéã§é¢é£ãã圱é¿ãçµæãããããå¯èœæ§ããããŸãã""以äžãç æ ççåŠçå€åãšèªèŠçç¶ã®èšŽãã玹ä»ããŸãã1) è¡äžäºé žåççŽ ã®å¢å 2) åŒåžæµæã®å¢å 3)è¡äžé žçŽ é£œå床ã®äœäž 4ïŒå¿ææ°ã®å¢å 5ïŒïŒå¿èºèœåã®äœäž 6)ç²åŽæ 7) åŒåžæ°ã®å¢å 8)åŒåžå°é£ã»æ¯åã 9ïŒé ç 10ïŒããŸã 11ïŒããããæã»æã 12ïŒç æ°ïŒè³ªçç¥çµéå®³ïŒ 13ïŒå ±æåã®äœäž 14ïŒãããã»ããã¿ã»ç®èç å€ã䌎ãç®èããªã¢æ©èœäœäž" |
29) N95ãã§ã€ã¹ãã¹ã¯ã¯ããŸããé çãšé¢ä¿ãããã®ã§ããããïŒÂ 2021幎ãã€ãã㯠| "N95 "䜿çšåŸã«åŒåžæ§ã¢ã«ã«ããŒã·ã¹ãšäœçé žã¬ã¹ãæ€åºããããæ¥æ§åŒåžæ§ã¢ã«ã«ããŒã·ã¹ã¯ãé çãäžå®ãéããçèã®ãããããåŒãèµ·ããå¯èœæ§ããããæ¬ç ç©¶ã§ã¯ã被éšè ã®çç¶ãåŒåžæ§ã¢ã«ã«ããŒã·ã¹ãšäœçé žã¬ã¹ã«ãããã®ã§ããããšãå®éçã«ç€ºãããã" |
30) COVID-19ãããã£ããã«ãæè¡è ããŒã ãå°å³ãªãã¹ã¯ãèŠçŽãããã€ã€ãŒãºã2020幎 | ããããããã®ç²åããéããããšã§ããã¹ã¯ã¯åŒåžããã«ããããã®ã§ããN95ãã¹ã¯ã¯ãé žçŽ æåéã5ïœ20ïŒ æžå°ããããšèšãããŠããŸããããã¯å¥åº·ãªäººã§ãã£ãŠã倧ããªè² æ ã§ããããŸãããµãã€ãã®åå ã«ãªãããšããããŸãããã¹ã¯ãé·ãã€ããŠãããšãèºãå·ããããšããããŸããåŒåžå°é£ã®æ£è ããã«ãšã£ãŠã¯ãçåœãè ããå¯èœæ§ããããã®ã§ãã |
31) å»åž«70åãBen Weytsæ°ã«å ¬éæžç°¡ãåŠæ ¡ã§ã®ããŠã¹ãã¹ã¯ã®çŸ©åä»ãã廿¢ããã-ãã«ã®ãŒ, ã¯ãŒã«ããã¥ãã€ãã¥ãŒã¹, 2020 | "ãã©ã³ãã«å°æ¹ã®Ben Weytsæè²å€§è£ïŒN-VAå·ïŒå®ã®å ¬éæžç°¡ã§ã70人ã®å»åž«ããåŠæ ¡ã§ã®ããŠã¹ãã¹ã¯ã®çŸ©ååããæåž«ã«ãçåŸã«ã廿¢ããããèŠè«ããŠãããWeytsæ°ã¯æ¹éã転æããã€ããã¯ãªãããã ãå»åž«ãã¡ã¯ãBen Weyts倧è£ã®äœæ¥æ¹æ³ãçŽã¡ã«æ€åããããæ±ããŠããïŒåŠæ ¡ã§ã®ãã¹ã¯ççšçŸ©åã¯ãªãããªã¹ã¯ã°ã«ãŒããä¿è·ãããªã¹ã¯ãããã¡ã€ã«ã®å¯èœæ§ããã人ã¯å»åž«ã«çžè«ããããã«ãšã®ã¢ããã€ã¹ã®ã¿ã§ããã" |
32) COVID-19ãã³ãããã¯æã®ä¹³å¹Œå ãžã®ãã¹ã¯ã®å±éºæ§ã UC Davis Healthã2020幎 | ããã¹ã¯ã¯ãå°ããªãåæ§ã«ã¯çªæ¯ã®å±éºããããŸãããŸãããã¹ã¯ã®åœ¢ç¶ãè£ çæã«ãã£ãŠã¯ãåŒåžå°é£ã«é¥ãå¯èœæ§ããããŸãããã®ãããªå Žåã¯ããã¹ã¯ãå€ããããã«ããå¿ èŠããããŸãããšUC Davisã®å°å ç§å»ã¯è¿°ã¹ãŠããŸãã ã¬ãã»ãŽã¡ã³ã»ãã«ã»ãªã¹ã.ã2æ³æªæºã®åã©ãã¯ããã¹ã¯ã確å®ã«å€ãããšãã§ãããçªæ¯ããå¯èœæ§ããããŸãããããã£ãŠã幌ãåã©ãã«ã¯ãã¹ã¯ãæ¥åžžçã«äœ¿çšãã¹ãã§ã¯ãããŸãã...ã幌ãåã©ãã»ã©ããã¹ã¯ãé©åã«ççšããããã¹ã¯ã®äžã«æã䌞ã°ããæ±æãããå¯èœæ§ã®ãããã¹ã¯ã«è§Šããå¯èœæ§ãé«ããªããŸãããšè¿°ã¹ãŠããŸãã ãã£ãŒã³ã»ãã©ã ããŒã°ã®å°å ææçéšé·ã UCãã€ãã¹å°å ç é¢."ãã¡ãããããã¯åã ã®åäŸã®çºéã¬ãã«ã«äŸåããŸãããããã10代ãŸã§ã¯ããã¹ã¯ããªã¹ã¯ããã倧ããªå©çãããããå¯èœæ§ã¯äœããšæããŸãã". |
33) ã³ããã-19ãã§ã€ã¹ãã¹ã¯ççšã«ããå¯äœçšã®ãã¡ãçæãã¹ãéèŠãªå¯èœæ§, ã©ããã¡ãªãŒã, 2020 | ããã¹ã¯ãããŠãããšãåãæ¯ãç®ã«å ¥ãããã®ãããç®ãè§Šããããšããè¡åãçããã3) æãæ±ããŠãããšãèªåã«ãææãã 4) ãã¹ã¯ãããŠãããšãåŒåžãèŠãããªãããã«ããããŸã§åãåºããŠããäºé žåççŽ ã®äœå²ãããåŒåžãµã€ã¯ã«ã®ãã³ã«åžã蟌ãŸããããããã®çŸè±¡ã¯åŒåžåæ°ãšæ·±ããå¢å ããããã¹ã¯ãããææè ãæ±æããã空æ°ãããå€ãæ¡æ£ããã°ãcovid-19ã®è² æ ãæªåãããå¯èœæ§ãããããŸããåŒåžã®äº¢é²ããŠã€ã«ã¹éãèºã«æŒã蟌ãã°ãææè ã®èšåºç¶æ ãæªåãããå¯èœæ§ãããã5ïŒèªç¶å ç«ã®å¹åã¯ãŠã€ã«ã¹éã«å€§ããäŸåããã6ïŒèªç¶å ç«ãšãŠã€ã«ã¹éãšã®é¢é£æ§ã7ïŒèªç¶å ç«ãšãŠã€ã«ã¹éãšã®é¢é£æ§ããªã©ã§ããããã¹ã¯ããåŒåžã«ãã£ãŠç¶ç¶çã«äŸçµŠãããã¹ã¯ã®çå°ã«ãã£ãŠææãããæ°Žèžæ°ã«ãã£ãŠãSARS-CoV-2ãæŽ»æ§ãç¶æã§ããæ¹¿åºŠã®é«ãç°å¢ã決å®ãããšããŠã€ã«ã¹éã®å¢å ïŒåŒæ°ãŠã€ã«ã¹ã®ååžå ¥ã«ãã£ãŠïŒã決å®ãããããã£ãŠèªç¶å ç«ã®æåãšææã®å¢å ãåŒãèµ·ããå¯èœæ§ãããã" |
34) COPDæ£è ã«ãããN95ãã¹ã¯ã®äœ¿çšã«é¢ãããªã¹ã¯ãã§ã³ã2020幎 | ã97åã®è¢«éšè ã®ãã¡ãCOPDã®7åã¯è©Šéšæéäžãã£ãšN95ãè£ çããŠããŸããã§ããããã®ãã¹ã¯éççšçŸ€ã§ã¯ãè±åœä¿®æ£å»åŠç ç©¶è©è°äŒã®åŒåžå°é£ã¹ã±ãŒã«ã¹ã³ã¢ãé«ããFEV1 ãã¹ã¯äœ¿çšæåçŸ€ã«æ¯ã¹ãäºæž¬å€ã«å¯Ÿããå²åãé«ãã£ããä¿®æ£å»åŠäŒåŒåžå°é£ã¹ã±ãŒã«ã¹ã³ã¢3以äžïŒãªããºæ¯167ïŒ95% CI 8.4ïœ>999.9ïŒP = .008ïŒãŸãã¯FEVâ§1ïŒãªããºæ¯167ïŒ95% CI 8.4ïœ>999.9ïŒP = .008ïŒã§ãã£ãïŒ1 999.9; P = .001ïŒã¯ïŒN95 ãççšããªããªã¹ã¯ãšé¢é£ããŠããïŒåŒåžåæ°ãè¡äžé žçŽ é£œå床ãåŒæ°äºé žåççŽ æ¿åºŠãN95䜿çšååŸã§ææå·®ã瀺ããã" |
35) 2æ³ä»¥äžã®åäŸã«ãã¹ã¯ã¯å±éºããããå»çå£äœãèŠåã ãžã£ãã³ã¿ã€ã ãºã2020幎 | "2æ³ä»¥äžã®åã©ãã¯ãåŒåžãå°é£ã«ããçªæ¯ã®å±éºæ§ãé«ããã®ã§ããã¹ã¯ãççšãã¹ãã§ã¯ãªããšãå»çå£äœãçºè¡šããã³ãããŠã€ã«ã¹å±æ©ããåéããåœå®¶ãšããŠä¿è·è ãžã®ç·æ¥ã¢ããŒã«ãéå§ããŸããã"ãã¹ã¯ã¯ãä¹³å ã¯ç©ºæ°ã®éè·¯ãçãã®ã§åŒåžãå°é£ã«ããŸãã" å¿èãžã®è² æ ãå¢å ãããã¹ã¯ã¯åã©ãã«ãšã£ãŠç±äžçã®ãªã¹ã¯ãé«ãããšãåäŒã¯çºè¡šããŸããã" |
36) ãã§ã€ã¹ãã¹ã¯ã«ã¯åé¡ããããäžéšã®ã«ãã人ã®å¥åº·ã害ããå±éºæ§ãããïŒæè·æŽŸ, ã¹ãã³ãµãŒ, 2020 | "ãã§ã€ã¹ãã¹ã¯Â Asthma Canadaã®ç€Ÿé·å ŒCEOã§ããVanessa Foranã¯ããã¹ã¯ãççšããã ãã§åæ¯çºäœã®ãªã¹ã¯ãçããå¯èœæ§ããããšè¿°ã¹ãŠããŸãã |
37) COVID-19 ãã¹ã¯ã¯äººéã«å¯Ÿãã眪ã§ãããå ç«¥èåŸ ã§ãã, ã°ãªãŒãããªããœã³, 2020 | "åãæ¯ã®ååžå ¥ã¯ãééããªãé žçŽ æ¬ ä¹ãšäºé žåççŽ ã®æ°Ÿæ¿«ãåŒãèµ·ããã人éã®è³ã¯é žçŽ æ¬ ä¹ã«å¯ŸããŠéåžžã«ææã§ããããšãåãã£ãŠããŸããäŸãã°æµ·éЬã®ç¥çµçްèã¯ã3å以äžé žçŽ ããªããšçããŠãããªãã®ã§ããæ¥æ§æã«ã¯ãé çãç æ°ãããŸããéäžåã®äœäžãåå¿é床ã®äœäžãªã©ãèªç¥ã·ã¹ãã ã®åå¿ã«åœ±é¿ãåºãŸããããããæ ¢æ§çãªé žçŽ æ¬ ä¹çã«ãªããšãæ £ããããããããã®çç¶ã¯ãã¹ãŠãªããªããŸããããããå¹çã¯èœã¡ããŸãŸã§ãè³å ã®é žçŽ äžè¶³ã¯é²è¡ããŠãããŸããç¥çµå€æ§çŸæ£ã¯ãçºçãŸã§ã«æ°å¹Žããæ°å幎ãããããšãããã£ãŠããŸãã仿¥ãããªããé»è©±çªå·ãå¿ãããšããŠããè³ã®äžã®æ éã¯20幎ã30幎åã«ãã§ã«å§ãŸã£ãŠããã¯ãã§ããåã©ãã¯åŠã¶ããã«è³ãå¿ èŠãšããè³ã¯æ©èœããããã«é žçŽ ãå¿ èŠãšããŠããã®ã§ãã ãã®ããã«èšåºç ç©¶ã¯å¿ èŠãªããããã¯åçŽã§ãè°è«ã®äœå°ã®ãªãççåŠçãªããšã§ããæèçã«ãæå³çã«é žçŽ æ¬ ä¹ãåŒãèµ·ããããšã¯ãçµ¶å¯Ÿã«æå³çãªå¥åº·è¢«å®³ã§ããã絶察çãªå»åŠççŠå¿ã§ããã" |
38) ãã¹ã¯ãåã©ããã¡ã«äžãã圱é¿ã«ã€ããŠã®ç ç©¶ã¡ã«ã³ã©ç€Ÿã2021幎 | "åã©ããã¡ã®ãã¹ã¯äœéšãèšé²ããåã®ç»é²ããŒã¿ãããã€ã©ã€ã©ãéäžå°é£ãåŠç¿é害ãªã©ã身äœçãå¿ççãè¡åçãªåé¡ã瀺ãããŸããã2020幎æ¥ã®åŠæ ¡éé以æ¥ãåã©ãã®æ³šææ¬ é¥å€åæ§é害ïŒADHDïŒã®è¬ç©æ²»çãæ±ãã芪ãå¢å ããŠããŸããè±åœããã®èšŒæ ã¯ãåŠæ ¡ã¯ä¿å¥åœå±ãèšã£ããããªã¹ãŒããŒã¹ãã¬ãããŒã§ã¯ãªãããšã瀺ããŠãããåŠæ ¡ã§ã®ææçã®æž¬å®å€ã¯å°å瀟äŒãšåãã§ãé«ãã¯ãªãã£ããå€§èŠæš¡ã©ã³ãã 忝èŒè©Šéšã§ããã¹ã¯ççšã¯SARS-CoV-2ã®æ¡æ£ãäœæžããªãããšã瀺ãããã" |
39) ãã¹ã¯ãå
ç«¥ã®èº«äœçãå¿ççãè¡åçè² æ
ã«ãªããšããæ°ããªç ç©¶çµæãçºè¡šããã2021幎ãããŒã« https://www.researchsquare.com/article/rs-124394/v2 | "æ°ãã ç ç©¶25,000人以äžã®åŠç«¥ã察象ãšãããã®èª¿æ»ã§ã¯ããã¹ã¯ãåŠç«¥ã®èº«äœçãå¿ççãè¡åçãªå®³ãåãŒããŠããããã¹ã¯ççšã«äŒŽã24ã®æç¢ºãªå¥åº·åé¡ãæããã«ãªããŸããããã®çµæã¯æ°ã«ãªããŸããã29.7%ãæ¯åãã26.4%ãããŸããçµéšããã»ããæ°çŸäººãåŒåžã®å éãèžã®å§è¿«ãè±åãçæã®æèé害ãçµéšããŠããŸããã |
40) ä¿è·çšãã§ã€ã¹ãã¹ã¯ãå£è å€ç§å»ã®æè¡äžã®é žçŽ åããã³å¿æç¶æ ã«åãŒã圱é¿ã«ã€ããŠ2021幎ãã¹ã«ãŒã | ããµãŒãžã«ã«ãã¹ã¯ã§èŠãããFFP2ãè£ çãã20人ã®å€ç§å»å šå¡ã«ãããŠãåèè¡é žçŽ æ¿åºŠã®æžå°ã確èªãããã2Â å¿ææ°ã®äžæã«äŒŽããè¡å97.5%çšåºŠã§ãã£ã飜å床ããè¡åŸ94%ãèšé²ããããŸããæ¯åãã軜ãé çãèªããããŸããã" |
41) å€ç§çšãã¹ã¯ããã³FFP2/N95ãã§ã€ã¹ãã¹ã¯ã®å¿èºéåèœåãžã®åœ±é¿, ãã¡ã€ã±ã³ã¶ãŒ, 2020 | å¥åžžè ã«ãããŠãææ°ãå¿èºéåèœåãå¿«é©æ§ã¯ãµãŒãžã«ã«ãã¹ã¯ã§äœäžããFFP2/N95ãã§ã€ã¹ãã¹ã¯ã§é«åºŠã«æãªããããããããã®ããŒã¿ã¯ãä»äºäžãéåäžã®ãã§ã€ã¹ãã¹ã¯ã®ççšæšå¥šã«éèŠã§ããã" |
42) å人é²è·å ·ã«é¢é£ããé ç-COVID-19æéäžã®ç¬¬äžç·å»çåŸäºè ã«ãããæšªæçç ç©¶, ãªã³ã°, 2020 | "å»çåŸäºè ã®å€ãã¯ãPPEé¢é£é çãde novoã§çºçããããæ¢åã®é çéå®³ãæªåãããã" |
43) å»åž«ããã³å»çé¢ä¿è ãããã«ã®ãŒåœå±ããã³ãã«ã®ãŒã®å šã¡ãã£ã¢ã«å®ãŠãå ¬éæžç°¡ã 米åœã¹ãã¬ã¹ç ç©¶æã2020幎 | "ãã¹ã¯ççš "ã«å¯äœçšããªãããã§ã¯ãããŸããã é žçŽ æ¬ ä¹çïŒé çãåãæ°ãåŠæ æãéäžåäœäžïŒãããªãæ©ãèµ·ãããé«å±±ç ãšåããããªå¹æããããŸãããã¹ã¯ççšã«ããé çãå¯éŒ»è çŸæ£ãåŒåžåšçŸæ£ãéåŒåžã蚎ããæ£è ãæ¯æ¥èŠãããããã«ãªã£ãããŸããèç©ãããCO2ã¯çäœã®æå®³ãªé žæ§åãæããå ç«åã«åœ±é¿ãäžããããã¹ã¯ãäžé©åã«äœ¿çšããå ŽåããŠã€ã«ã¹ã®ææãå¢å ãããšèŠåããå°éå®¶ãããã»ã©ã§ãã" |
44) ãã¹ã¯ã®åå©çšã¯ã³ãããŠã€ã«ã¹ææãªã¹ã¯ãé«ããå¯èœæ§ããããšå°éå®¶ãææ, ã©ã®ã, 2020 | ãäžè¬åžæ°ã¯ãç æ°ã§ãªãéãããŸãå»çåŸäºè ã®å©èšããªãéãããã§ã€ã¹ãã¹ã¯ãççšããã¹ãã§ã¯ãããŸãããããªãŒãºå士ã¯è¿°ã¹ãŠããŸããããã«ãè¡åã«åé¡ããããšãéã«ææã®ãªã¹ã¯ãé«ããŠããŸãå¯èœæ§ããããšä»ãå ããŸãããäŸãã°ãå€åºå ã§æãæŽããããã¹ã¯ã®äžéšãé¡ãè§Šã£ãŠããŸããææããŠããŸãã®ã§ãã" |
45) ãã¹ã¯ã®äžã§äœãèµ·ãã£ãŠããã®ãïŒÂ ã©ã€ãã2021幎 | ã仿¥ã®ã¢ã¡ãªã«äººã¯ãå°ãªããšãéå»ãšçŸåšã®ä»ã®å€ãã®äººã ãšæ¯èŒããŠãå¹³åçã«ããªãè¯ãæ¯ãæã£ãŠããŸããããã«ãããããããããã¯ããŠã³ã匷å¶ãã¹ã¯ãç§ãã¡ã®å£ã«äžãã圱é¿ã«ã€ããŠã»ãšãã©è°è«ãããŠããªãããšãããããããã«ãç§ãã¡ã¯å£ã®äžã®å¥åº·ã«ã€ããŠååã«èããŠããªãã®ã§ãã |
46) å¥åº·ãªå°å ã«ããããã¹ã¯è£ çæãšéè£ çæã®åžæ°äžäºé žåççŽ æ¿åºŠã®å®éšçè©äŸ¡A Randomized Clinical trial2021幎ããŽã¡ã©ãã | "å€§èŠæš¡èª¿æ» "ã宿œÂ ãã€ãã§è¡ããã25930人ã®åã©ãã®ããŒã¿ãçšãã芪åãžã®æªåœ±é¿ã«é¢ãã調æ»ã§ã¯ãåå ããåã©ãã®ãã¡68%ã錻ãšå£ãèŠããã®ãççšããéã«åé¡ããã£ãããšã瀺ãããŠããŸãã" |
47) NMå· åäŸãã¡ã¯100åºŠã®æãã®äžããã¹ã¯ãã€ããŠèµ°ãããšã匷èŠããã芪ãã¡ã¯åæã«åºãã2021幎ãã¹ãã¹ | ãå šç±³ã§ã¯ãCOVID-19ã«ããåã©ãã®çåçã¯99.997%ã§ãã ãã¥ãŒã¡ãã·ã³ã§ã¯ãåäŸã®COVID-19çäŸã®ãã¡ãããã0.7%ã®çäŸãÂ å ¥é¢.åã©ããã¡ã極ããŠÂ äœç 床ã»äœæ»äº¡Â COVID-19ããããã¹ã¯ã®çŸ©ååã¯åäŸãã¡ã«è² æ ãããã圌ãèªèº«ã®å¥åº·ã幞çŠã«å®³ãåãŒããŠãã" ã |
48) ã«ããä¿å¥çãã°ã©ãã§ã³å ¥ãäœ¿ãæšãŠãã¹ã¯ã«æ³šæåèµ·ãçºè¡š, CBC, 2021 | ãã«ããä¿å¥çã¯ãã°ã©ãã§ã³ãå«ãäœ¿ãæšãŠãã§ã€ã¹ãã¹ã¯ã䜿çšããªãããã«ããåœæ°ã«å§åããŠããŸããã«ããä¿å¥ç éç¥æžãçºè¡Â éææ¥ã«çºè¡šãããççšè ã¯ççŽ ååã®åå±€ã§ããã°ã©ãã§ã³ãåžã蟌ãå¯èœæ§ããããšè¿°ã¹ãŸãããææ¯ãªç²åãå«ããã¹ã¯ã¯ãäžéšã®å»çæœèšã§é åžãããå¯èœæ§ãããã" |
49) COVID-19ãã¹ã¯ççšã«ãããã€ã¯ããã©ã¹ããã¯åžå
¥ãªã¹ã¯ã«é¢ããæ§èœè©Šéšæã2021幎 ã§ãã ã°ã©ãã§ã³ã¯å®å šãïŒÂ  | ããµãŒãžã«ã«ãã¹ã¯ãã³ããã³ãã¹ã¯ããã¡ãã·ã§ã³ãã¹ã¯ã掻æ§çãã¹ã¯ã®ççšã¯ãç¹ç¶ç¶ã®ãã€ã¯ããã©ã¹ããã¯åžå ¥ãªã¹ã¯ãé«ãããããã¹ãŠã®ãã¹ã¯ã¯ãæ³å®æéå ïŒ4æéæªæºïŒã«äœ¿çšããå ŽåãæŠããŠæé²ãæžå°ããããN95ã¯ç¹ç¶ç¶ã®ãã€ã¯ããã©ã¹ããã¯åžå ¥ãªã¹ã¯ãäœããç°ãªãæ¶æ¯ååŠçå·¥çšãçµããã¹ã¯ãå䜿çšãããšãç²åç¶ïŒäŸïŒç²ç¶ãã€ã¯ããã©ã¹ããã¯ïŒããã³ç¹ç¶ç¶ãã€ã¯ããã©ã¹ããã¯ã®åžå ¥ãªã¹ã¯ãé«ãŸãå¯èœæ§ããããŸãã玫å€ç·æ¶æ¯ã¯ç¹ç¶ç¶ãã€ã¯ããã©ã¹ããã¯ã®åžå ¥ã«å¯ŸããŠæ¯èŒç匱ã广ã瀺ãããã埮çç©åŠçãªèгç¹ããæå¹æ§ã蚌æãããã°ããã¹ã¯ã®åäœ¿çšæã®åŠçããã»ã¹ãšããŠæšå¥šã§ãããN95ãã¹ã¯ã®ççšã«ããããã¹ã¯éççšæã«æ¯ã¹ãçç¶ãã€ã¯ããã©ã¹ããã¯ã®åžå ¥ãªã¹ã¯ã25.5åäœæžãããã" |
50) ãããã¯ãããžãŒç±æ¥ã®ã°ã©ãã§ã³ããã¹ã¯ã«äœ¿çšããã¡ãŒã«ãŒãçžæ¬¡ã - å®å šæ§ãžã®æžå¿µãæµ®äž2021幎ãã¡ã€ããŒã | ãã°ã©ãã§ã³ã«é¢ããåæã®æžå¿µã¯ãå¥ã®çš®é¡ã®ççŽ ã«é¢ãã以åã®ç ç©¶ã«ç«¯ãçºããŠããã ã«ãŒãã³ãããã¥ãŒã.ãã®çµæãç¹ç¶ç¶ã®ç©è³ªã®äžã«ã¯ãåžã蟌ããšæ·±å»ãªè¢«å®³ããããããã®ãããããšã倿ãããã«ãŒãã³ãããã¥ãŒãã®è¿çžçš®ã§ããã°ã©ãã§ã³ã«ããåæ§ã®æžå¿µãããã®ã§ã¯ãªãããšããã®ãããã®ç ç©¶ã®åœç¶ã®çåã§ããã æå®³ã«ãã (现é·ããäœå€ã«æåºããã«ãããªã©ïŒããããã¥ãŒããããå®å šãªçŽ æã§ããããšã瀺åãããŠããŸãããããããããå®å šã§ããããšããããšã¯ããå®å šã§ããããšããããšã§ã¯ãããŸãããçŸåšã®ç ç©¶ã«ãããšããã®ææã¯ããŸãååãªå®å šæ§è©Šéšãè¡ããã«ãåžã蟌ãå¯èœæ§ã®ããå Žæã«äœ¿ãã¹ããã®ã§ã¯ãããŸããã 誀ã£ãŠåžã蟌ã¿ãèºã®ææãªäžå±€éšã«éããå¯èœæ§ã®ãã補åã«ã¯äœ¿çšããªãããšã." |
51)Â åŠæ ¡ã§ã®å¹Œå ã®ãã¹ã¯ã¯èšèªç¿åŸã«å®³ãåãŒã, ãŠã©ã«ã·ã¥, 2021 | ããŸããé¡ãç¹ã«å£ãèŠãããšã¯ãåäŸãçåŸãåžžã«è¡ã£ãŠããèšèªç¿åŸã«ãšã£ãŠéåžžã«éèŠã§ããããã«ãå£ãèŠãããšã¯ã³ãã¥ãã±ãŒã·ã§ã³ã«äžå¯æ¬ ã§ããã ãã§ãªããè³ã®çºéã«ãäžå¯æ¬ ã§ãã"調æ»ã«ãããšãäœæåŸäžåž¯ã®åäŸã¯4æ³ãŸã§ã«ãé€è²è ãšãã質ã®é«ãå¯Ÿé¢æéãæã€å¯è£å±€ã®åäŸã«æ¯ã¹ã3,000äžèªå°ãªãèšèãèãããšã«ãªããŸãã" (https://news.stanford.edu/news/2014/november/language-toddlers-fernald-110514.html)." |
52) åäŸçšãã¹ã¯ããå±éºãªç åäœãæ€åºãããåççãªæ ¹æ ã2021幎 | ããããªãå·ã²ã€ã³ãºãã«ã®ä¿è·è ã°ã«ãŒããããããªã倧åŠã®ç ç©¶æã«ãã¹ã¯6æãéããççšåŸã®ãã¹ã¯ããæ€åºãããæ±æç©è³ªã®åæãäŸé ŒããŸããããã®çµæã5æã®ãã¹ã¯ããã¯ããªã¢ãå¯çè«ãçèã§æ±æãããŠããããã®ãã¡3æã¯å±éºãªç åæ§çŽ°èãšèºçã®åå ãšãªã现èã§ããããšã倿ããã®ã§ãããŸããSARS-CoV-2ãå«ããŠã€ã«ã¹ã®æ€åºãå¯èœã§ããã1æã®ãã¹ã¯ããæ€åºããããŠã€ã«ã¹ã¯1çš®é¡ïŒã¢ã«ã»ã©ãã£ã³ã»ãã«ãã¹ãŠã€ã«ã¹1ïŒã ãã§ãã...ã3åã®1ã¯ãé«èçãåŒãèµ·ãã1ã€ä»¥äžã®çްèã«æ±æãããŠããã3åã®1ã¯ãæçç©è³ªèæ§ã®ããå±éºãªçŽ°èæ§ç åäœã«æ±æãããŠãããããã«ãçºç±ã朰çãã«ãã³ãã€ãŒã¹ãèææçãæº¶é£èææçãæ¯åšç ãããããŒå±±æç¹ç±ãªã©ã®åå ãšãªãç åäœãªã©ãå±éºåºŠã®äœãç åäœã確èªãããŸããã" |
53) SARS-CoV-2ãã³ãããã¯æã®åŒ·å¶ãã¹ã¯ã«ããããã¹ã¯ç®èçãïŒãã€ãã®å»çåŸäºè ããã³éå»çåŸäºè 550人ã®ããŒã¿ããããŒãµãŒãã2021幎 | ããã¹ã¯ççšæéã¯çç¶ã®æç çã«ææãªåœ±é¿ãåãŒããïŒpïŒ0.001ïŒãIVåéæçã¯ãçç¶ã®ãªãäººã«æ¯ã¹ãŠçç¶ã®ããäººã§ææã«å€ãã£ããïŒpïŒ0.001ïŒãã¢ãããŒæ§ç®èçãæã€åå è ã§ã¯çç¶ã®å¢å ã¯èŠãããªãã£ããHCWã¯éHCWã«æ¯ã¹ãé¡ã®ã¹ãã³ã±ã¢è£œåã®äœ¿çšé »åºŠãææã«é«ãã£ãïŒp = 0.001ïŒã" |
54) ãã¹ã¯ççšãåŒåžåã®äºé žåççŽ æ¿åºŠã«äžãã圱é¿, AAQR/Geiss, 2020 | "æ€åºãããäºé žåççŽ ã®æ¿åºŠã¯ã2150±192ïœ2875±323ppmã®ç¯å²ã§ããããã¹ã¯ãããŠããªãæã®äºé žåççŽ ã®æ¿åºŠã¯500ïœ900ppmãšã°ãã€ãããããŸãããäºåäœæ¥ãšãã¬ãããã«ã§ã®éæ¢ç¶æ ã§ã¯ãããããçŽ2200ppmã®äºé žåççŽ æ¿åºŠãæ€åºãããŸããã3km/h-1ã®é床ïŒãã£ãããšããæ©è¡ããŒã¹ïŒã§æ©ããšãããããªå¢å ã芳å¯ãããã"æ€åºãããç¯å²ã®æ¿åºŠã¯ãç²åŽãé çãéäžåäœäžãªã©ã®å¥œãŸãããªãçç¶ãåŒãèµ·ããå¯èœæ§ãããã |
55) æè¡äžã®çŽ°èæ±ææºãšããŠã®ãµãŒãžã«ã«ãã¹ã¯, Zhiqing, 2018 | "SMã®çŽ°èæ±ææºã¯ãORç°å¢ãããè¡è ã®äœè¡šã§ãã£ããããã«ãè¡è ã¯æè¡ã®ãã³ã«ãç¹ã«2æéãè¶ ããæè¡ã§ã¯ããã¹ã¯ã亀æããããšãæšå¥šããã" |
56) ãã¹ã¯ã»ãã«ãã¬ã³ã®è¢«å®³ã¯å埩äžèœã«ãªãå¯èœæ§ãããããã·ãŒã2021幎 | ããã¹ã¯ççšè ã«1幎éãå²ãŸããŠãããšãç¥çµã®çºéãçããªææã«é¡ã®ããŒã³ãŒãèªèãæãªãããFFAã®å®å šãªçºéãå±éºã«ãããããã®ã§ã¯ïŒä»è ãšã®åé¢ãèŠæ±ãã瀟äŒççžäºäœçšãæžããããšã¯ãèªéçã«èŠããããããªæœåšçãªçµæãããããã®ã§ããããïŒè³ã®çºéã劚ããªãããã«ãé¡èªèèŠèŠç¥çµãžã®èŠèŠå ¥åã劚ããªããšç¢ºä¿¡ã§ããã®ã¯ãã€é ã§ããããïŒåºæ¿ã«å¹²æžããæéã¯ãã©ã®çšåºŠãŸã§ãªãçµæãªãã«èš±ãããã®ã§ããããïŒãããã¯ãã¹ãŠãçŸåšã®ãšããçãã®ãªã質åã§ãããç§ãã¡ã«ã¯ããããŸãããæ®å¿µãªãããç§åŠçã«ã¯ãããç§ãã¡ãé¡ã«å¯Ÿããè³ã®çºéãå°ç¡ãã«ããŠããŸã£ãããç§ãã¡ãããŠããŸã£ãããšããã¹ãŠå ã«æ»ãããããªæ²»çæ³ã¯ä»ã®ãšãããªãã®ãããããŸããã |
57) ãã¹ã¯ã¯äººã殺ã, ã°ãã¹ãã³, 2021 | "ãã¹ã¯ã®ççšã¯ãå 害è ã®å¿åæ§ãé«ãããšåæã«ã被害è ã®äººéæ§ã倱ãããããšã«ãªããŸããããã¯å ±æã劚ããæŽåãæ®ºäººãåã¥ãããã®ã§ãã"ãã¹ã¯ã¯å ±æãæããããåãé€ãã®ã«åœ¹ç«ã¡ãä»äººããã¹ã¯ããã人ã«èšãããã®ãªãè¡çºãããããšãå¯èœã«ããŸãã" |
58) ãã³ãã³ã®é«æ ¡æåž«ããã§ã€ã¹ãã¹ã¯ããå ç«¥èåŸ ã®ã²ã©ããèš±ãããã圢æ ããšææããã©ãŒã2020幎 | ããã¡ãŒã«ãŒãœã³æ°ã¯ã¡ãŒã«ã®äžã§ããã¹ã¯ççšãæ³å¶åãããã£ã³ããŒã³ããæ¥ãã¹ãè¶çªåãèŠããããæ¿æ²»åããšåŒã³ãå ¬è¡è¡çãšããããããæåŸãšéµå®ãã匷å¶ãããã®ã ãšææããããŸãããã¹ã¯ççšãã匷å¶çãªèªå·±æ·åãã«ãªãããããã²ã©ããèš±ããããå ç«¥èåŸ ã身äœçæŽè¡ã§ããããšãè¿°ã¹ãŠããã |
59) è±åœæ¿åºé¡§åããã¹ã¯ã¯å®è³ªçã«äœãããªããæ °ãã®æ¯åžãã«éããªãããšãèªããZeroHedge, 2021 | "è±åœæ¿åºã¯æ¬æ¥ããèªç±ã®æ¥ãã宣èšããŠããŸãããããã¯Â åŠãææã¯ãããããã®ãšã¢ããŸã«ã¯ãã¹ã¯ãéãããŠããŸãããã¹ã¯ãå¹ããªãããããšææãããåœæ°ã¯äœããããªããã°ãªããªããšèŠæ±ãã圌ãã¯ãã¹ã¯ãæã«å ¥ããããããã¯åãªãæ °ãã®æ¯åžã«éããªãããšä»ãå ãããããããä»ãããã¯å®çããç§ãã¡ã¯æªãè¡ããå®çãããŠããŸããäžçäžã®ãã¹ã¯çŸ©ååãèŠãŠãææçãšéãåãããŠãããã¹ã¯çŸ©ååããããªã广ãããããããã¯ããããŸããããšã¢ã¯ãœã³ã¯ããã«ææãããã©ããªãã¹ã¯ã«ã€ããŠãèšããããšã¯ããããæã€ãã©ã¹ã®å¹æã¯å°ããããŠæž¬å®ã§ããªãããšã§ãããšãä»ãå ããŸããã |
60) ãã¹ã¯ãåœãã®å®å šæ§ãšæ¬åœã®å±éºæ§ããã®1ãç Žç æ§ãã¹ã¯ã®åŸ®ç²åãšèºã®è匱æ§2020幎ããããŽã©ã€ | ãå€ç§å»ã¯ãã«ãŒããšããŒãºããªããžãé€ãããã¹ã¯ã®ã©ã®éšåã«ã決ããŠè§Šããªãããã«èšç·ŽãããŠããŸãããããªããã°ããã®ãã¹ã¯ã¯äœ¿ãç©ã«ãªããªããšå€æããã亀æãããããšã«ãªããŸããæè¡æ åœè ã¯ããã以å€ã¯ãã¹ã¯ã«è§Šããªãããã«å³ããæè²ãããŠããŸããããããäžè¬ã®äººããã¹ã¯ã®ãããããªéšåãè§Šã£ãŠããã®ãèŠãããããšããããŸãããã¹ã¯ã®å è£ ããåãåºããã°ããã®ãã®ã§ãããåžã蟌ãã®ã«æé©ãšã¯èšããªã埮ç²åãç¹ç¶ãå«ãŸããŠããããšããäžã®åçã§ç€ºãããŠããŸããç¹ã«ãã§ã€ã¹ãã¹ã¯ããåžã蟌ãã 埮ç²åã«å¯Ÿãããã¯ããã¡ãŒãžåå¿ããã®ä»ã®å ç«ã»ççã»ç¹ç¶èœçްèåå¿ã«ã€ããŠã®ãããªãæžå¿µã¯ããããªãç ç©¶ã®å¯Ÿè±¡ã§ããã¹ãã§ãããã¹ã¯ãåºãæ®åããŠãããªãã°ããã¹ã¯ã®ç¹ç¶ãç°å¢ããã³çç©åŠçãªç Žçãåžã蟌ãå¯èœæ§ããäœå人ãã®äººã ã«ãšã£ãŠæ¥åžžçã«ç¶ããŠããããšã«ãªãããã®ããšã¯ãè·æ¥äžã®å±éºã«è©³ããå»åž«ãç«åŠè ã«ãšã£ãŠææ ®ãã¹ãããšã§ããã" |
61) å»ççšãã¹ã¯ã ããµã€ã2020幎 | ããã¹ã¯ã¯ãå³ããããã¿ãå Žåã«ãã£ãŠã¯çºç±ãªã©ãåŒåžåšææçã®çç¶ããã人ã ãã䜿çšããããã«ããŸãããããã¹ã¯ã¯ãå»çåŸäºè ãåŒåžåšææè ã®äžè©±ãããŠãã人ããŸãã¯å¯æ¥ã«æ¥è§ŠããŠãã人ããããã¯å»åž«ã®æç€ºã«ãã£ãŠççšãã¹ãã§ããå¥åº·ãªäººãåŒåžåšææçã«ãããã®ãé²ãããã«ãã¹ã¯ãççšããããšã¯ãå¥åº·ãªäººãççšãããã¹ã¯ãç æ°ã«ãªãã®ãé²ãã®ã«æå¹ã§ããããšã瀺ã蚌æ ããªãããã§ãã |